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Abstract
Intramedullary nail fixation versus locking plate fixation for
adults with a fracture of the distal tibia: the UK FixDT RCT
Matthew L Costa,1,2,3* Juul Achten,1,3 Susie Hennings,1 Nafisa Boota,1
James Griffin,1 Stavros Petrou,1 Mandy Maredza,1 Melina Dritsaki,3
Thomas Wood,2 James Masters,2,3 Ian Pallister,4 Sarah E Lamb1,3
and Nick R Parsons1 on behalf of the UK FixDT trial investigators
1Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK
2Department of Trauma and Orthopaedics, University Hospitals Coventry and Warwickshire NHS
Trust, Coventry, UK
3Oxford Trauma, Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal
Sciences, University of Oxford, Oxford, UK
4Medical School, Swansea University, Swansea, Wales
*Corresponding author matthew.costa@ndorms.ox.ac.uk
Background: The best treatment for fractures of the distal tibia remains controversial. Most of these
fractures require surgical fixation, but the outcomes are unpredictable and complications are common.
Objectives: To assess disability, quality of life, complications and resource use in patients treated with
intramedullary (IM) nail fixation versus locking plate fixation in the 12 months following a fracture of the
distal tibia.
Design: This was a multicentre randomised trial.
Setting: The trial was conducted in 28 UK acute trauma centres from April 2013 to final follow-up in
February 2017.
Participants: In total, 321 adult patients were recruited. Participants were excluded if they had open
fractures, fractures involving the ankle joint, contraindication to nailing or inability to complete
questionnaires.
Interventions: IM nail fixation (n = 161), in which a metal rod is inserted into the hollow centre of the
tibia, versus locking plate fixation (n = 160), in which a plate is attached to the surface of the tibia with
fixed-angle screws.
Main outcome measures: The primary outcome measure was the Disability Rating Index (DRI) score,
which ranges from 0 points (no disability) to 100 points (complete disability), at 6 months with a minimum
clinically important difference of 8 points. The DRI score was also collected at 3 and 12 months. The
secondary outcomes were the Olerud–Molander Ankle Score (OMAS), quality of life as measured using
EuroQol-5 Dimensions (EQ-5D), complications such as infection, and further surgery. Resource use was
collected to inform the health economic evaluation.
Results: Participants had a mean age of 45 years (standard deviation 16.2 years), were predominantly male
(61%, 197/321) and had experienced traumatic injury after a fall (69%, 223/321). There was no statistically
significant difference in DRI score at 6 months [IM nail fixation group, mean 29.8 points, 95% confidence
interval (CI) 26.1 to 33.7 points; locking plate group, mean 33.8 points, 95% CI 29.7 to 37.9 points;
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adjusted difference, 4.0 points, 95% CI –1.0 to 9.0 points; p = 0.11]. There was a statistically significant
difference in DRI score at 3 months in favour of IM nail fixation (IM nail fixation group, mean 44.2 points,
95% CI 40.8 to 47.6 points; locking plate group, mean 52.6 points, 95% CI 49.3 to 55.9 points; adjusted
difference 8.8 points, 95% CI 4.3 to 13.2 points; p < 0.001), but not at 12 months (IM nail fixation group,
mean 23.1 points, 95% CI 18.9 to 27.2 points; locking plate group, 24.0 points, 95% CI 19.7 to 28.3
points; adjusted difference 1.9 points, 95% CI –3.2 to 6.9 points; p = 0.47). Secondary outcomes showed
the same pattern, including a statistically significant difference in mean OMAS and EQ-5D scores at 3 and
6 months in favour of IM nail fixation. There were no statistically significant differences in complications,
including the number of postoperative infections (13% in the locking plate group and 9% in the IM nail
fixation group). Further surgery was more common in the locking plate group (12% in locking plate group
and 8% in IM nail fixation group at 12 months). The economic evaluation showed that IM nail fixation
provided a slightly higher quality of life in the 12 months after injury and at lower cost and, therefore, it was
cost-effective compared with locking plate fixation. The probability of cost-effectiveness for IM nail fixation
exceeded 90%, regardless of the value of the cost-effectiveness threshold.
Limitations: As wound dressings after surgery are clearly visible, it was not possible to blind the patients
to their treatment allocation. This evidence does not apply to intra-articular (pilon) fractures of the distal
tibia.
Conclusions: Among adults with an acute fracture of the distal tibia who were randomised to IM nail
fixation or locking plate fixation, there were similar disability ratings at 6 months. However, recovery across
all outcomes was faster in the IM nail fixation group and costs were lower.
Future work: The potential benefit of IM nail fixation in several other fractures requires investigation.
Research is also required into the role of adjuvant treatment and different rehabilitation strategies to
accelerate recovery following a fracture of the tibia and other long-bone fractures in the lower limb.
The patients in this trial will remain in longer-term follow-up.
Trial registration: Current Controlled Trials ISRCTN99771224 and UKCRN 13761.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 25.
See the NIHR Journals Library website for further project information.
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Plain English summary
The shin bone (tibia) is the most commonly broken major bone in the leg. Injuries in the lower part ofthe shin bone (distal tibia) nearly always require hospital admission and usually require surgery, resulting
in prolonged periods (months) away from work and social activities.
Existing research suggested that modern ‘locking’ plate fixation and intramedullary (IM) nail fixation are
the most common types of operation performed for this fracture. However, it was not clear which provides
the better outcome for patients.
In this study, we asked 321 adult patients, who were having surgery for a fracture of the distal tibia, to have
either IM nail fixation or locking plate fixation. The decision about which type of fixation to use was made
using randomisation, which is a process similar to tossing a coin. The patients reported their own outcome at
3, 6 and 12 months after their fracture using the Disability Rating Index (DRI). We also collected information
on quality of life, complications and costs from patient-completed questionnaires and other NHS sources.
The DRI score of both groups of patients improved in the months after their surgery, although patients
were not back to normal, even 1 year later. The patients who had IM nail fixation of their tibial fracture
recovered more quickly than the patients with locking plate fixation, but there were no differences
between the treatments after 6 months. There was no difference in the number of complications suffered
by each group, but further surgery was more common in the locking plate group. The economic analysis
showed that IM nail fixation was cheaper than locking plate fixation.
This important study shows that IM nail fixation provides slightly better quality of life for patients in the
12 months following a fracture of the distal tibia and costs less than locking plate fixation. If surgery to fix
the distal tibia is required, IM nail fixation is the preferred treatment.
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Scientific summary
Background
The tibia is the most commonly broken major bone in the leg. Injuries require hospital admission, usually
require surgery and result in prolonged periods away from work and social activities. The treatment of
displaced, extra-articular fractures of the distal tibia (lower third) remains controversial. These injuries are
particularly difficult to manage because of the limited soft-tissue cover, poor vascularity of the area and
proximity of the fracture to the ankle joint. Infections, non-union and malunion of the fracture are
well-recognised complications.
Surgical treatment options include intramedullary (IM) nail fixation, ‘locking’ plate and screw fixation and
external fixation. External fixators may be beneficial in selected cases but, in the UK, the IM nail and locking
plate options are most commonly used for extra-articular fractures. Mid-shaft fractures of the tibia are generally
treated successfully with locked IM nails. However, in the more distal metaphyseal region of the tibia, the
fixation may be less stable. The bolts or screws that are inserted into the nail may break, malalignment of the
bone may occur and there is a risk that the nail will penetrate into the ankle joint. The development of locking
plates, in which a thread on the head of the screws locks into the holes in the plate to create a ‘fixed-angle’
construct, has led to a recent increase in the use of locking plate fixation. However, locking plates are not
without risks and they require greater soft-tissue dissection, which carries a risk of infection, wound breakdown
and damage to the surrounding structures.
The UK Fixation of Distal Tibia Fractures trial was designed to compare IM nail fixation with locking plate
fixation for adult patients with a displaced, extra-articular fracture of the distal tibia.
Methods
All of the centres involved in the trial were UK NHS acute trauma centres. All of the centres provided
definitive surgical fixation of this type of fracture in their hospital as part of routine clinical practice.
Inclusion criteria
The inclusion criteria for this trial were that the patient:
l was aged ≥ 16 years
l had any fracture that involves the distal tibial metaphysis, which was defined as a fracture extending
within 2 Müller squares of the ankle joint
l would, in the opinion of the attending surgeon, benefit from internal fixation of the fracture.
Exclusion criteria
The exclusion criteria for this trial were that:
l there is, in the opinion of the attending surgeon, a contraindication to IM nailing: the presence of total
knee replacement OR that the medullary canal is too narrow OR there is a pre-injury deformity of the
medullary canal OR it is not possible to achieve fixation of four cortices with screws distal to the fracture
l the fracture is open
l there is a contraindication to anaesthesia
l there is evidence that the patient would be unable to adhere to trial procedures or complete questionnaires
l the fracture extends into the ankle joint (i.e. intra-articular fracture).
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Interventions
Each patient had the allocated surgery according to the preferred technique of the operating surgeon.
However, as there were a large number of centres and a large number of surgeons at each of these
centres, no individual surgeon was expected to perform more than a handful of the procedures. Therefore,
the effect of the surgeon and their learning curve would be minimal in this particular trial.
Intramedullary nail fixation
The IM nail is inserted at the proximal end of the tibia and passed down the hollow centre (medullary canal)
of the bone in order to hold the fracture in the correct (anatomical) position. The reduction technique, the
surgical approach, the type and size of the nail, the configuration of the proximal and distal interlocking
screws and any supplementary device or technique was left at the discretion of the surgeon as per standard
clinical practice.
Locking plate fixation
A locking plate is inserted at the distal end of the tibia and passed under the skin onto the surface of the
bone. Again, the details of the reduction technique, the surgical approach, the type and position of the
plate, the number and configuration of fixed-angle screws and any supplementary device or technique
were left to the discretion of the surgeon. The only stipulation was that fixed-angle screws must be used
in at least some of the distal screw holes; this is standard practice with all distal tibia locking plates.
Outcomes
The primary outcome was the Disability Rating Index (DRI), a validated scale that assessed patients’ rating of
their own disability. The DRI contains 12 items and provides an overall score from 0 to 100 points, in which
0 points represents no disability and 100 points represents complete disability. The secondary outcome
measures in this trial were the Olerud–Molander Ankle Score (OMAS), the EuroQol-5 Dimensions (EQ-5D)
health-related quality-of-life questionnaire score and complications at 3, 6 and 12 months postoperatively.
Resource use was collected to inform the health economic evaluation.
Randomisation
A minimisation algorithm was used to allocate participants. Following informed consent, the method of
fixation was allocated using a secure, centralised, web-based randomisation service, delivered by an
accredited Clinical Trials Unit (Warwick Clinical Trials Unit). The allocated treatment was reported to the
research associate, who informed the treating surgeon. Stratification by centre helped to ensure that any
clustering effect related to the centre itself was equally distributed in the trial arms. Stratification on the
basis of age was used to discriminate between younger patients with normal bone quality sustaining
high-energy fractures and older patients with low-energy (fragility) fractures related to osteoporosis.
Blinding
The type of fixation determines the site of clearly visible surgical scars. Specifically, the insertion of an
IM tibial nail requires a surgical incision at the knee. Therefore, the patients could not be blind to their
allocated treatment. In addition, the treating surgeons were also not blind to the treatment but did not
take part in the postoperative assessment of the patients. The functional outcome data were collected via
patient questionnaires and entered into the trial central database by a research assistant or data clerk in
the trial central office. The radiographs were reviewed by an independent assessor who was not involved
in any other data collection or analysis.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xx
Statistical analysis
The main analysis investigated differences in the primary outcome measure, the DRI score, at 3, 6 and
12 months on an intention-to-treat basis. The primary outcome end point was at 6 months.
Health economic evaluation
An economic evaluation was conducted from the recommended NHS and Personal Social Services (PSS)
perspective. An incremental cost-effectiveness analysis was performed, which is expressed in terms of
incremental cost per quality-adjusted life-year (QALY) gained.
Results
Patients
A total of 321 patients took part in the trial between April 2013 and May 2016 at 28 UK acute trauma
centres. Over 80% of participants provided follow-up data at each time point and data were 88%
complete for the primary outcome measure at 6 months.
Primary outcome measure
There was no statistically significant difference in DRI score at 6 months [IM nail fixation group, mean
29.8 points, 95% confidence interval (CI) 26.1 to 33.7 points; locking plate group, mean 33.8 points,
95% CI 29.7 to 37.9 points; adjusted difference 4.0 points, 95% CI –1.0 to 9.0 points; p = 0.11]. There
was a statistically significant difference in DRI score at 3 months in favour of IM nail fixation (IM nail
fixation group, mean 44.2 points, 95% CI 40.8 to 47.6 points; locking plate group, mean 52.6 points,
95% CI 49.3 to 55.9 points; adjusted difference 8.8 points, 95% CI 4.3 to 13.2 points; p < 0.001), but not
at 12 months (IM nail fixation group, 23.1 points, 95% CI 18.9 to 27.2 points; locking plate group, 24.0
points, 95% CI 19.7 to 28.3 points; adjusted difference 1.9 points, 95% CI –3.2 to 6.9 points; p = 0.47).
Conclusions from the secondary per-protocol (per-treatment) analysis of the DRI did not differ from those
of the primary intention-to-treat analysis.
Secondary outcome measures
The secondary patient-reported outcome measures showed the same effect and the same pattern over
time as the DRI score. Each measure showed a statistically significant difference in favour of IM nail fixation
at 3 months, which gradually reduced at 6 months and then 12 months after the injury. There was a
statistically significant difference in the OMAS at 6 months (mean difference –6.0 points, 95% CI –11.2 to
–0.7 points; p = 0.026) in favour of the IM nail fixation group. Similarly, there was a statistically significant
difference in the EQ-5D health-related quality-of-life index at 6 months (mean difference –0.063 points,
95% CI –0.12 to –0.01 points; p = 0.033) in favour of the IM nail fixation group.
In terms of ‘complications local to the distal tibia fracture’, 14 (9%) patients in the IM nail fixation group
and 21 (13%) in the locking plate group were treated with antibiotics for a wound infection in the first
6 weeks after surgery. Revision of the internal fixation was uncommon in both groups: two patients (1%)
in the IM nail fixation group and five patients (3%) in the locking plate group (p = 0.283). However,
removal of metalwork was required in 11 (7%) patients in the IM nail fixation group and 14 (9%) in the
locking plate group. Other local complications were rare in both groups. There was no evidence of a
difference in ‘systemic complications related to the injury or its treatment’ or in the number of ‘unrelated
adverse events’.
The health economic evaluation showed that patients who were allocated to the IM nail fixation group
experienced a small increase in QALYs in the base-case analysis (0.01 QALYs, 95% CI –0.03 to 0.06
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QALYs) over the 12-month follow-up and mean NHS and PSS costs were significantly lower in the IM nail
fixation group (–£970, 95% CI –£1690 to –£260; p = 0.05). The difference in cost was driven by the lower
number of outpatient visits and the lower rate of further surgery in the IM nail fixation group. Therefore,
the incremental cost-effectiveness ratio indicates IM nail fixation is the ‘dominant’ procedure, as average
costs for this intervention were lower and average benefits were greater than in the locking plate group.
The probability of cost-effectiveness for IM nail fixation exceeded 90% regardless of the value of the
cost-effectiveness threshold.
Discussion
This trial provides strong evidence that IM nail fixation and locking plate fixation provide similar outcomes
at 6 and 12 months following an extra-articular fracture of the distal tibia. However, patients receiving IM
nail fixation reported less disability, better ankle function and improved health-related quality of life at
3 months. The economic evaluation showed that IM nail fixation provided slightly higher quality of life in
the 12 months after injury and at a lower cost and, therefore, it was cost-effective compared with locking
plate fixation. The probability of cost-effectiveness for IM nail fixation exceeded 90%, regardless of the
value of the cost-effectiveness threshold.
In conclusion, among adults with an acute fracture of the distal tibia randomised to IM nail fixation or
locking plate fixation, there were similar disability ratings at 6 months. However, recovery across all
outcomes was faster in the nail fixation group and costs were lower.
Trial registration
This trial is registered as ISRCTN99771224 and UKCRN 13761.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Adapted with permission from Achten et al.1 This is an Open Access article distributed in accordancewith the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is
properly cited. See: http://creativecommons.org/licenses/by/4.0/.
Background
The tibia is the most commonly broken major bone in the leg. In younger patients, fractures of the tibia
typically occur during sporting activity or road traffic accidents, but in older patients they can happen
during simple falls. Injuries usually require hospital admission and surgery, resulting in prolonged periods
(months) away from work and social activities.
The treatment of displaced, extra-articular fractures of the distal tibia (lower third) remains controversial.
These injuries are difficult to manage because of the limited soft-tissue cover, poor vascularity of the area
and proximity of the fracture to the ankle joint. Infections, non-union and malunion are well-recognised
complications.
Non-operative treatment is one option and avoids the risks associated with surgery. Sarmiento et al.,2 in
2003, reviewed 450 closed fractures of the distal tibia following functional bracing: 13.1% developed a
malunion (defined as > 7° of angulation or 12 mm of shortening). Another study,3 using a more robust
definition of 10 mm of shortening and 5° of angulation, found a higher rate of malunion (26.4%). In
this study, Böstman et al.3 treated patients using a long leg cast, and failure to maintain reduction led to
surgical treatment with an intramedullary (IM) nail. Thirty-two out of 103 cases required nailing at a mean
of 9 days following injury. Two patients in this group, and three in the non-operative group, went on to
have a non-union.3 Union rates were faster with IM nailing than with conservative treatment and median
values were 12.5 and 14.5 weeks, respectively (p < 0.001).3 Digby et al.4 also found that non-operative
treatment for tibial fractures in the metaphyseal region leads to unacceptable deformity and ankle
stiffness. Therefore, operative treatment is now the treatment of choice for the majority of patients with
a fracture of the distal tibia.
Surgical treatment options are expanding and include locked IM nails, plate and screw fixation, as well as
external fixator systems, including the Ilizarov frame and hybrid fixators. External fixators may be beneficial
in selected cases, particularly those involving severe soft-tissue injuries, but, in the UK, the IM nail and
‘locking’ plate options are most commonly used for extra-articular fractures. Mid-shaft fractures of the tibia
are generally successfully treated with locked IM nails. However, in the more distal metaphyseal region of
the tibia, the fixation may be less stable.5 The bolts or screws that are inserted into the nail may break,6
malalignment may occur7 and there is a risk that the nail will penetrate into the ankle joint.8,9
The development of locking plates, in which a thread on the head of the screws locks into the holes in the
plate to create a ‘fixed-angle’ construct, has led to a recent increase in the use of locking plate fixation.
However, locking plates are not without risks and they require greater soft tissue dissection, which carries
a risk of infection, wound breakdown and damage to the surrounding structures.10
In a retrospective study11 of 111 patients with extra-articular fractures of the distal tibia (4 to 11 cm
proximal to the plafond), a comparison was made between IM nail and locking plate fixation. Seventy-six
fractures were treated with an IM nail and 37 were treated with a medial plate.11 Nine patients (12%) had
a delayed union or non-union in the IM nail fixation group and one patient (2.7%) had a non-union after
locking plate fixation (p = 0.10). Angular malalignment of ≥ 5° occurred in 22 patients with IM nails (29%)
and two with locking plates (5.4%; p = 0.003). The authors concluded that fractures of the distal tibia may
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be treated successfully with locking plates or IM nails, but that delayed union, malunion and secondary
procedures were more frequent after IM nailing. Janssen et al.12 found similar results: delayed union was
higher in the IM nail fixation group (25%) than in the locking plate fixation group (16.7%) and rotational
malalignment was also higher in the IM nail fixation group (16.7%) than in the locking plate group (0%).
However, this was not a randomised controlled trial (RCT) and the results do need to be interpreted with
some caution. Randomised prospective assessment are necessary to further clarify these issues and provide
information about costs associated with these fractures.11
Only two prospective RCTs had been published when this trial began.13,14 In the first,13 64 patients were
randomised to either IM nail or plate fixation for the treatment of a closed extra-articular fracture. The time to
union was found to be similar for the two groups and there was no difference in terms of Olerud–Molander
Ankle Score (OMAS) at 2 years. However, a significant difference was observed in the number of wound
complications: one in the IM nail fixation group versus seven in the plate group. This paper concluded that IM
nailing is the treatment of choice for this injury. However, the method of randomisation was poorly described
and so bias in group assignment may have occurred. The study used traditional (non-locking plates) rather
than the newer fixed-angle devices. Furthermore, the study included patients with Tschene classification C2
soft-tissue injuries, which may have influenced the results. The second trial14 randomised 111 patients to
either IM nail fixation or ‘locking’ plate fixation. This trial also showed no difference in the time to union but,
1 year after the injury, there was some evidence of improved American Orthopaedic Foot and Ankle Society
functional scores in the IM nail fixation group. However, this was a single-centre investigation and > 20% of
the patients in the trial were lost to follow-up.
In a meta-analysis, Zelle et al.15 reviewed 1125 extra-articular fractures of the distal tibia. They reported
that non-union, malunion and infection rates were similar for patients undergoing IM nailing and locking
plate fixation. It must be noted that none of the studies in the review was a RCT.
Pre-pilot trial
We performed a pilot study involving 24 patients with extra-articular fractures of the distal tibia that were
closed or Gustilo and Anderson grade 1.16 The study was a RCT with clinical assessment, functional
outcomes and radiological images performed at baseline and at 6 weeks, and 3, 6 and 12 months post
surgery. The study was performed to obtain an estimate of the potential effect size to inform the sample
size calculation for a larger definitive trial and to assess recruitment rates and study feasibility.
The study had 12 patients in each group. There was no statistically significant difference between the
groups 6 months after the injury but there was a 10-point difference [standard deviation (SD) 20 points] in
the Disability Rating Index (DRI)17 in favour of the IM nail group. More secondary procedures were required
in the ‘locking’ plate fixation group. There was also a difference in the cost of the implants.
This pilot study, combined with the literature review, provided compelling evidence to support the
development of a definitive RCT in multiple centres.
Null hypothesis
There was no difference in the DRI score between adults with a displaced fracture of the distal tibia
treated with locking plate fixation versus IM nail fixation.
INTRODUCTION
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Objectives
The primary objective was to estimate the difference in the DRI scores between the trial treatment groups
at 6 months after injury.
The secondary objectives were to:
1. estimate the difference in early functional status at 3 months and later functional status at 12 months
2. estimate the difference in health-related quality of life between the trial treatment groups in the first
year after injury
3. determine the complication rate of IM nail fixation versus locking plate fixation in the first year after
injury, including radiological complications – non-union and malunion
4. investigate, using appropriate statistical and economic analytical methods, the resource use, costs and
comparative cost-effectiveness of IM nail fixation versus locking plate fixation.
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Chapter 2 Methods
Adapted with permission from Achten et al.1 This is an Open Access article distributed in accordancewith the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is
properly cited. See: http://creativecommons.org/licenses/by/4.0/.
Trial design
We conducted this project as a two-phased study. Phase 1 (internal pilot) determined the expected rate of
recruitment in a large-scale multicentre RCT in this complicated area of trauma research. Phase 2 (main
phase) was a RCT in 28 acute trauma centres across the UK.
Internal pilot summary
The pilot took place in six centres over a period of 6 months. Screening logs were kept at each site to
determine the number of patients assessed for eligibility and reasons for any exclusion. In addition, the
number of eligible and recruited patients, and the number of patients who declined consent/withdrew,
were recorded.
Main randomised controlled trial summary
All adult patients presenting at the trial centres with an acute fracture of the distal tibia were potentially
eligible to take part in the trial. The broad eligibility criteria ensured that the results of the study could
readily be generalised to the wider patient population. A computer-generated randomisation sequence,
stratified by centre and age, was produced and administered independently by a secure web-based service,
Warwick Clinical Trials Unit (WCTU). Randomisation was on a 1 : 1 basis to either IM nail fixation or
locking plate fixation. Both of these operations are widely used within the NHS and all of the surgeons in
the chosen centres were familiar with both techniques.
Baseline demographic data, radiographs and pre-injury functional data using the DRI and the OMAS
questionnaire were collected. The patients were also asked to fill out the EuroQol-5 Dimensions (EQ-5D)
health-related quality-of-life questionnaire twice at baseline; once to indicate their typical pre-injury health
status and a second time to indicate their current post-injury status.
In conjunction with the clinical team, a research associate performed a clinical assessment and recorded
any early complications at 6 weeks, and a radiograph was taken. A further clinical assessment and
radiograph was also taken at 12 months postoperatively to detect late complications. Functional outcome,
health-related quality of life and resource use questionnaires were collected at 3, 6 and 12 months
postoperatively.
Participants
Inclusion criteria
The inclusion criteria for this trial were that the patient:
l was aged ≥ 16 years
l had any fracture that involves the distal tibial metaphysis, which was defined as a fracture extending
within 2 Müller squares of the ankle joint18 (a Müller square is shown in Figure 1)
l had a closed fracture
l would, in the opinion of the attending surgeon, benefit from internal fixation of the fracture.
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Exclusion criteria
The exclusion criteria for this trial were that:
l there is, in the opinion of the attending surgeon, a contraindication to IM nailing – the presence of
total knee replacement OR the medullary canal is too narrow OR there is a pre-injury deformity of the
medullary canal OR it is not possible to achieve fixation of four cortices with screws distal to the fracture
l the fracture is open
l there is a contraindication to anaesthesia
l there is evidence that the patient would be unable to adhere to trial procedures or
complete questionnaires
l the fracture extends into the ankle joint (i.e. intra-articular fracture).
Screening and recruitment
All of the centres involved in the trial were UK NHS acute trauma centres. All of the centres provided
definitive surgical fixation of this type of fracture in their hospital as part of routine clinical practice.
The internal pilot informed, and tested, the recruitment rate for the main trial.16 Recruitment took place in
six trial centres over a period of 6 months. The expected rate of recruitment was based on the pre-pilot
study performed at the lead centre. The average recruitment rate for the pre-pilot study, during which
24 patients were recruited, was 1.3 patients per month. The other centres involved in the trial were all
regional trauma units with similar catchment areas to the lead centre. However, a conservative recruitment
rate of 0.75 patient per centre per month (pcpm) was estimated for the full trial based on our previous
experience of multicentre trials, in which we found that recruitment outside the lead centre was at a lower
rate. Our plan was to progress to the main phase if this recruitment rate could be achieved at the end of
the internal pilot. Our intention was to recruit 320 participants, from a minimum of 18 centres in total
(including the lead centre), over a 30-month period.
Screening logs were collected throughout the trial to assess the main reasons for patient exclusion as well
as the number of patients unwilling to take part. Patients were screened by the research associates in the
emergency department and trauma unit at the trial centres. The trial was carried out in accordance with
the Mental Capacity Act 200519 and the procedures for undertaking trials in ‘emergency settings’ were
followed as described in detail in Consent. The consent procedures were reviewed at the end of the pilot
period.
FIGURE 1 Müller square.18 Reproduced with permission. Copyright by AO Foundation, Biel, Switzerland.
METHODS
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Consent
Patients with a fracture of the distal tibia are admitted to hospital, through the emergency department,
to a trauma ward. Patients are in pain and often treated with opiate-based painkillers during the initial
treatment of their injury, so mental capacity may be impaired. However, although surgical treatment for a
closed fracture of the tibia is urgent, it is not a time-critical intervention. In fact, traditionally, surgeons
have deliberately waited a day or more before operating in order to let soft-tissue swelling settle. Once the
leg is immobilised in a plaster cast, the pain is much better controlled, so mental capacity usually returns
quite quickly following admission to the trauma ward.
During the internal pilot phase of the trial, we monitored the number of patients with impaired capacity
and reviewed these data in conjunction with the Trial Steering Committee (TSC). In the context of this
injury, by the time the patient was due to have surgery, none of the potentially eligible patients was
judged to have reduced capacity according to the clinical team responsible for patient care. Therefore,
informed consent from the patient was obtained by the local research associate before surgery. Patients
were provided with verbal and written information about the study.
For those patients who withdraw from the trial after written consent had been obtained, data obtained up
to the point of withdrawal have been included in the final analysis.
Randomisation
Following informed consent, the method of fixation was allocated using a secure, centralised, web-based
randomisation service, delivered by an accredited clinical trials unit (WCTU). The randomisation service was
available 24 hours each day to facilitate the inclusion of all eligible patients. The allocated treatment was
reported to the research associate, who informed the treating surgeon. The surgeon then arranged the
allocated surgery on the next available trauma operating list, as per standard practice at that institution;
this ensured the integrity of the randomisation process. Allocation was implemented using a minimisation
algorithm (sometimes referred to as adaptive randomisation) that attempts, at recruitment of each new
patient, to balance the marginal totals for each level of the stratification factors. Experience indicates that,
for studies in which some centres recruit only a relative small number of patients, this method tends to
perform better than conventional stratification methods and may provide potential gains in efficiency.20
Stratification by centre helped to ensure that any clustering effect related to the centre itself was equally
distributed in the trial arms. The catchment area (the local population served by the hospital) was similar
for all of the hospitals, each hospital being a trauma unit dealing with these fractures on a daily basis.
Although it could have been possible that the surgeons at one centre may have been more expert in one
or the other treatment than those at another centre, all of the recruiting hospitals were chosen on the
basis that both techniques were routinely available at the centre, that is, theatre staff and surgeons were
equally familiar with both forms of fixation. This did not eliminate the surgeon-specific effect of an
individual at any one centre.21 However, fixation of a fracture of the tibia is not an uncommon procedure
and many surgeons will be involved in the management of this group of patients: between 10 and
30 surgeons at each centre, including consultants and trainees. Therefore, we expected that each individual
surgeon would operate on only two or three patients enrolled in the trial – and indeed this was the case –
greatly reducing the risk of a surgeon-specific effect on the outcome at any one centre.
Stratification on the basis of age was used to discriminate between younger patients with normal bone
quality sustaining high-energy fractures and older patients with low-energy (fragility) fractures related to
osteoporosis. The stratification would have helped to identify any effect related to the quality of the
patients’ bone. The use of dual-energy X-ray absorptiometry is widely regarded as the gold standard for
the assessment of bone density. However, such an investigation may be expensive and would not have
been routinely available at all centres.
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Therefore, we used age as a surrogate for bone density. In a large study in Norway, involving 7600 participants,
it was demonstrated that bone mineral density remains stable up until the age of 50 years. After the age of
50 years, bone mineral density decreased steadily in males, while in females there was an initial decline between
the ages of 50 and 65 years, with a further decline in both age groups thereafter.22 Over 1000 patients with a
fracture were recently assessed in a study by Court-Brown et al.23 This study confirmed that there is a clear
bimodal distribution according to the age of the patient. The crossover of the two peaks of incidence was
around 50 years of age. These studies provide strong evidence that patients > 50 years of age become
increasingly vulnerable to fragility fractures. Therefore, we chose an age of 50 years as the stratification cut-off
point for this trial.
Sequence generation
A minimisation algorithm was used to allocate participants, so no random sequences were generated
before the study. This is standard practice for trials conducted at WCTU.
Blinding
The type of fixation determines the site of clearly visible surgical scars. Specifically, the insertion of an IM
tibial nail requires a surgical incision at the knee. Therefore, the patients could not be blind to their allocated
treatment. In addition, the treating surgeons were also not blind to the treatment, but did not take part in
the postoperative assessment of the patients. The functional outcome data were collected and entered into
the trial central database via questionnaire administered by a research assistant/data clerk in the trial central
office. The radiographs collected were reviewed by an independent assessor who was not involved in any
other data collection or analysis.
Post-randomisation withdrawals
Participants could decline to continue to take part in the trial at any time and without prejudice. The
participants were made aware that a decision to decline consent or withdraw would not affect the
standard of care that they would receive.
Participants had two options for withdrawal:
1. Participants could withdraw from completing any further questionnaires but allow the trial team to
continue to view and record any relevant hospital data that were recorded as part of normal standard
of care, including radiographs and further surgery information.
2. Participants could withdrawal wholly from the study and only data obtained up to the point of
withdrawal would be included in the final analysis of the study; thereafter, no further data were
collected for that participant.
Once withdrawn, the patient continued under the care of their surgical team, as per normal clinical
practice.
Interventions
All the hospitals involved in this trial used both methods of fixation as part of routine clinical care. Consultant
orthopaedic trauma surgeons supervised the surgery, all of whom were familiar with both techniques. Operative
fixation of fractures of the distal tibia usually takes place under a general anaesthetic, but this decision was made
by the attending anaesthetist as per their usual clinical practice.
Each patient had the allocated surgery according to the preferred technique of the operating surgeon.
Although the basic principles of IM nailing and locking plate fixation are inherent in the technique (see
Intramedullary nail fixation and Locking plate fixation), there are several different implant systems and
several different options for the positioning of the screws. Similarly, each surgeon would have made minor
modifications to their surgical technique according to preference and the specific pattern of each fracture.
METHODS
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In this trial, the details of the surgery were left entirely to the discretion of the surgeon, to ensure that the
results of the trial could be generalised to as wide a group of patients as possible. A copy of the ‘operating
record’ formed part of the trial data set.
Although all of the surgeons in the trial were familiar with both techniques, it is possible that an individual
surgeon may have had more experience with one technique than the other. In general, the proficiency of
an individual surgeon to perform the procedure may change over time, as the surgeon gains experience
and expertise. The term ‘learning curve’ is often used to describe this process. It was important to be aware
of this effect within the trial. Therefore, the operating time was recorded from the operative record for
each surgery, as a proxy to measure the task ‘efficiency’ of the surgeons (quality assurance of the clinical
process), and the number of complications (e.g. infections) at 6 weeks after surgery was also recorded as a
patient-based outcome related to surgeon ‘expertise’. However, as there were a large number of centres
and a large number of surgeons at each of these centres, no individual surgeon was expected to perform
more than a handful of the procedures. Therefore, the effect of the surgeon and their learning curve would
be minimal in this particular trial.
Intramedullary nail fixation
The IM nail is inserted at the proximal end of the tibia and passed down the hollow centre (medullary canal) of
the bone in order to hold the fracture in the correct (anatomical) position. The reduction technique, the surgical
approach, the type and size of the nail, the configuration of the proximal and distal interlocking screws and any
supplementary device or technique were left at the discretion of the surgeon, as per standard clinical practice.
Locking plate fixation
A locking plate is inserted at the distal end of the tibia and passed under the skin onto the surface of the
bone. Again, the details of the reduction technique, the surgical approach, the type and position of the
plate, the number and configuration of fixed-angle screws and any supplementary device or technique
were left to the discretion of the surgeon. The only stipulation was that fixed-angle screws must be used
in at least some of the distal screw holes – this is standard practice with all distal tibia locking plates.
Rehabilitation
All patients randomised into the two groups received the same standardised, written physiotherapy advice
detailing the exercises they needed to perform for rehabilitation following their injury. All of the patients in
both groups were advised to move their toes, ankle and knee joints fully within the limits of their comfort.
Weight-bearing status was recommended by the treating surgeon. In this pragmatic trial, any other
rehabilitation input beyond the written physiotherapy advice (including a formal referral to physiotherapy)
was left to the discretion of the treating clinicians. However, a record of any additional rehabilitation input
(type of input and number of additional appointments) together with a record of any other investigations/
interventions were requested as part of the 3-month, 6-month and 12-month follow-ups, which formed
part of the trial data set.
Outcomes
The primary outcome measure for this study was the DRI.17 The DRI is a validated questionnaire that is
self-reported (i.e. filled out by the patient).24 It consists of 12 items specifically related to function of the lower
limb and provides an overall score from 0 to 100 points, in which 0 points represents no disability and 100
points represents complete disability. These data were collected at baseline, 3, 6 and 12 months postoperatively
(Table 1). The DRI has been proven to be a robust and practical clinical and research instrument, with good
responsiveness and acceptability for assessment of disability caused by impairment in the lower limb.
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Existing guidance for the calculation of DRI scores is unclear as regards the appropriate way to calculate
overall scores in the presence of missing items; the most common approach is to take an average of
available item scores. Owing to the low number of missing items, all analyses presented used complete
cases only, that is, 12 complete item responses out of 12.
The secondary outcome measures in this trial were as follows:
The OMAS questionnaire is a self-administered patient questionnaire designed to assess ankle pain and
function. It is a good outcome tool for assessing symptoms after a fracture around the ankle joint.25 The
score is based on nine different items: (1) pain, (2) stiffness, (3) swelling, (4) stair climbing, (5) running,
(6) jumping, (7) squatting, (8) supports and (9) work/activities of daily living.16 The scoring system correlates
well with parameters considered to summarise the results after this type of injury and, therefore, is
recommended for use in scientific investigations.
The EQ-5D is a validated, generic health-related quality-of-life measure consisting of five questions
regarding five dimensions of health. The answers can be converted into a health utility score.26 It has good
test–retest reliability, is simple for patients to use and gives a single preference-based index value for
health status that can be used for broader cost-effectiveness comparative purposes.
All complications were recorded, including malunion, non-union, infection, wound complications, vascular
and neurological injury and venous thromboembolism. A record was also kept of any other surgery required
in relation to the index fracture, including removal of any surgical implant. The adverse events have been
broken down into ‘local complications related to the fracture or its treatment’, ‘systemic complications
potentially related to the fracture or its treatment’ and ‘unrelated adverse events’ during the 12 months
after the injury.
For the radiographic evaluation of complications, standard anteroposterior and lateral radiographs of the
tibia and fibula were taken at baseline, at 6 weeks and at 12 months after the injury, as described in
Outcomes. The radiographs were viewed using OsiriX software version 7.5 (Pixmeo, Berne, Switzerland).
The radiographs were reviewed by an independent trauma surgeon from University Hospitals Coventry &
Warwickshire NHS Trust. An assessment was made on the alignment of the tibia in both the coronal
(lateral) and sagittal (anteroposterior) views of the tibia, and there was also an assessment of any
shortening present.
TABLE 1 Follow-up measures
Time point Data collection
Baseline DRI, OMAS questionnaire, pre-injury and current EQ-5D and radiographs
6 weeks DRI, OMAS questionnaire, EQ-5D, record of complications or other interventions and resource use
questionnaire
3 months DRI, OMAS questionnaire, EQ-5D, record of complications or other interventions and resource use
questionnaire
6 months DRI, OMAS questionnaire, EQ-5D, record of complications or other interventions and resource use
questionnaire
12 months DRI, OMAS questionnaire, EQ-5D, radiographs, record of complications or other interventions and
resource use questionnaire
Reproduced with permission from Achten et al.1 This is an Open Access article distributed in accordance with the terms of
the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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Threshold values were used to define ‘malunion’ as follows:3
1. coronal angulation of the distal tibia fixation of > 5°
2. sagittal angulation of the distal tibia fixation of > 10°
3. shortening of > 10 mm.
Threshold values have been shown to be more reliable than absolute measurements of deformity in the
distal tibia (Thomas Wood, Department of Trauma and Orthopaedics, University Hospitals Coventry and
Warwickshire NHS Trust, 2016, unpublished data).
We used techniques common in long-term cohort studies to ensure minimum loss to follow-up, such as
collection of multiple contact addresses and telephone numbers, mobile phone numbers and e-mail
addresses. Considerable efforts were made, by the trial team, to keep in touch with patients throughout
the trial by means of newsletters, and so on.
Follow-up
Baseline, standardised radiographs were copied from the hospital picture archiving and communication
system. Copies of the baseline clinical report forms and images were sent to the trial co-ordinating centre.
As part of routine clinical practice, patients were seen in the outpatient fracture clinic on a regular basis after
this injury. For this trial, the sample size was based on the primary outcome measure at 6 months, when
patients with an uncomplicated fracture may be expected to return to normal activities; but to ensure that
all complications and secondary procedures were captured, we continued follow-up for 1 year.14
The research associate performed a clinical assessment and made a record of any early complications at
the 6-week routine follow-up appointment. Radiographs were taken at 6 weeks and 12 months (or before
12 months if the surgeon felt that the fracture was united). An uncomplicated fracture of the distal tibia
would be expected to be clinically united at 6 months after the injury. However, radiographic union may
lag behind the clinical picture. Therefore, the 12-month radiographs were used to assess if there are
long-term complications, such as non-union and arthritis of the ankle joint.
The outcome and resource use data were collected using questionnaires at 3, 6 and 12 months
postoperatively. Patients were asked to complete their 6-month and 12-month postoperative questionnaire
during their routine follow-up appointments if they had one or to return them by post if they did not have an
appointment at these time points. Text messages were sent to patients to inform them that a questionnaire
was due or was on its way. Text messages were only sent to those patients who had given their prior
consent to this by initialling the corresponding box on the consent form.
Adverse event management
Adverse events are defined as any untoward medical occurrences in a clinical trial participant that do not
necessarily have a causal relationship with the treatment.
Serious adverse events (SAEs) are defined as any untoward and unexpected medical occurrence that:
1. results in death
2. is life-threatening
3. requires hospitalisation or prolongation of existing inpatients’ hospitalisation
4. results in persistent or significant disability or incapacity
5. is a congenital anomaly or birth defect
6. is any other important medical condition that, although not included in the above, may require medical
or surgical intervention to prevent one of the outcomes listed.
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All SAEs were entered onto the SAE reporting form and faxed to a dedicated fax machine at WCTU within
24 hours of the investigator becoming aware of them. Once received, causality and expectedness, as
determined by the principal investigator at each centre, were confirmed by the chief investigator. SAEs that
were deemed to be unexpected and related to the trial were notified to the Research Ethics Committee
(REC) and sponsor within 15 days. All such events were reported to the TSC and Data Monitoring
Committee (DMC) at their subsequent meetings.
Serious adverse events that may have been expected as part of the surgical interventions, and that did
not need to be reported to the main REC, were complications of anaesthesia or surgery (e.g. wound
complications, infection, damage to a nerve or blood vessel and thromboembolic events) and secondary
operations for or to prevent infection, malunion or non-union or for symptoms related to the metalwork.
All participants experiencing SAEs were followed up until the end of the trial, as described in the protocol.
Risks and benefits
The risks associated with this study were predominantly those associated with the surgery: infection,
bleeding and damage to the adjacent structures such as nerves, blood vessels and tendons. Participants in
both groups had surgery and were potentially at risk from any/all of these complications. We believed that
the overall risk profile was similar for the two interventions, but assessment of the number of complications
in each group was a secondary objective of this trial.
Statistical analysis
Sample size
The minimum clinically important difference (MCID) is 8 points on the primary outcome (DRI) measurement
scale. The DRI is a 12-question, patient-reported, functional outcome measure (physical exercise or sports,
running, heavy physical work, heavy lifting, carrying a bag, leaning over a wash-stand, making a bed,
moderate physical work, walks, mounting stairs, sitting still more than briefly and dressing or undressing)
converted to a 100-point scale in which 0 points represents normal function and 100 points represents
complete disability. At an individual patient level, a difference of 8 points represents the ability to climb
stairs or run, with ‘some difficulty’ versus with ‘great difficulty’. At a population level, 8 points represents
the difference between a ‘healthy patient’ and a ‘patient with a minor disability’. In addition, 8 points
corresponds approximately to the clinically worthwhile benefit identified in other studies24 and is slightly
lower than the 10-point difference between treatment group means in our pre-pilot study.
The SD of DRI score in our pilot study was approximately 20 points; the sample size was also estimated for
a larger and smaller SDs to obtain an indication of the sensitivity to changes in this parameter. Assuming
the distribution of DRI score in the study populations to be approximately normal, which is consistent with
assumptions made for other reported trials using DRI as the primary outcome measure, Table 2 shows the
total trial sample size with two-sided significance set at 5% for various scenarios of power and sample SD.
In Table 2, the number of 264 patients, represented in bold, represented the most likely scenario, based
on our current knowledge, for 90% power to detect the selected MCID. Allowing a margin of 20% loss
during follow-up, this gives a value of 320 patients in total. Therefore, 160 patients randomised to each
group would provide 90% power to detect a difference of 8 points in the DRI score at 6 months, with
90% power at the 5% significance level.
Standard statistical summaries (e.g. medians and ranges or means and variances, dependent on the
assumed distribution of the outcome) and graphical plots are presented for the primary outcome measure
and all secondary outcome measures. Baseline data are summarised to check comparability between
treatment arms and to highlight any characteristic differences between those individuals in the study, those
who were ineligible and those who were eligible but withheld consent.
METHODS
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Analysis plan
The detailed statistical analysis plan was created by the trial statisticians and agreed by the DMC at the
start of the study, in line with standard operating procedures at WCTU. Any subsequent amendments to
this initial statistical analysis plan were clearly stated and justified to the DMC.
Software
All routine data reporting and final analysis was conducted using Stata® version 14 (StataCorp LP, College
Station, TX, USA).27
Data validation
Prior to formal analysis, data were checked for outliers, missing values and validated using the defined
score ranges for all outcome measures. Queries were reported to the trial co-ordinator and investigated
with the relevant recruiting centre if appropriate. Any subsequent changes to the database were recorded
in accordance with the relevant WCTU standard operating practice and the UK Fixation of Distal Tibia
Fractures (FixDT) trial data management plan.
Missing data
Data may not be available as a result of withdrawal of patients, lack of completion of individual data
items or loss to follow-up. Reasons for data ‘missingness’ were ascertained and reported as far as possible.
Any patterns of missingness were carefully considered, including, in particular, whether or not data could be
treated as missing completely at random. No formal statistical testing was planned to assess missingness, but
model assumptions were checked and patterns of missingness explored. If judged appropriate, missing data
in the primary outcome (DRI score) was imputed using the ice (imputation by chain equation) procedure in
Stata version 14. Any imputed data were on an individual-item level, as opposed to an overall score level.
Reasons for ineligibility, non-compliance, withdrawal or other protocol violations are stated and any patterns
are summarised.
Interim analyses
There were no planned interim analyses for the UK FixDT study.
Final statistical analyses
Null hypothesis
The null hypothesis for the UK FixDT study was that there is no difference in the DRI score between adult
patients with a fracture of the distal tibia treated with IM nail fixation versus locking plate fixation.
TABLE 2 Sample size at variable power and SD
SD (points)
Power, sample size (n)
80% 90%
15 112 150
20 198 264
25 308 412
Bold indicates the actual sample size chosen for this trial.
Reproduced with permission from Achten et al.1 This is an Open Access article distributed in accordance with the terms of
the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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Multilevel model
The main analysis plan was to investigate differences in the primary outcome measure, the DRI score at
6 months after surgery, between the two treatment groups on an intention-to-treat basis. In addition, early
functional status was also assessed and reported at 3 months and later functional status at 12 months. The
unadjusted differences between treatment groups were assessed using a Student t-test, based on a normal
approximation for the DRI score at 6 months, and at other occasions. Tests were two-sided and considered
to provide evidence for a significant difference if p-values are < 0.05 (5% significance level). Estimates of
treatment effects are presented with 95% confidence intervals (CIs).
In addition to the unadjusted analysis (t-tests), we planned to undertake regression analyses to adjust for
any imbalance between test treatments groups in patient age group, baseline pre-injury score and sex.
The fixed-effects analysis (linear regression model) was also generalised by adding a random effect for
recruiting centre to allow for possible heterogeneity in patient outcomes because of, more generally, the
recruiting centre. Outcome data were assumed to be normally distributed during modelling, but subsidiary
analyses were also undertaken after appropriate variance-stabilising transformations. The primary focus
was the comparison of the two treatment groups of patients and this was reflected in the analysis, which
was conducted together with appropriate diagnostic plots to check the underlying model assumptions.
Treatment effects are presented for both the unadjusted and adjusted analyses, with 95% CIs as
appropriate.
Any interactions between age group or sex and the main treatment effect were not expected to be
considerable, and the sample size calculations were not conducted with these potential analyses in mind.
Analyses were, however, undertaken for each of these variables. Formal interaction tests were conducted
and reported with appropriate 95% CIs.
Complications
The number of events were compared between treatment groups on an intention-to-treat basis, in line with
the main outcome analyses. Complications profiles are presented in three sections: (1) local complications
related to the fracture or its treatment, (2) systemic complications potentially related to the fracture or its
treatment and (3) unrelated adverse events within the 12-month time frame of the trial. These include
information from the 6-week follow-up appointment with the research associate, in conjunction with data
from patient-reported questionnaires at 3, 6 and 12 months post randomisation, and any other reports of
SAEs. The data were cross-referenced between multiple data sources and clinical judgement was used to
classify events in to the presented categories.
Exploratory analysis
To complement the preplanned analysis, a post hoc exploratory analysis using DRI score at all four time
points was conducted. This analysis simplified longitudinal data collected at four time points to a single
value, namely the area under the curve (AUC), and facilitated comparisons of the AUCs between
treatment groups. It is advisable, in the presence of missing data, to use summary statistics generated by
mixed models, as estimates will not be biased under the assumption that data are missing at random or
are missing completely at random.28 Therefore, we fitted a repeated measures mixed model, with the
same fixed-effect structure as used in the primary analyses (adjusted for sex and age group), but with a
three-level random-effects structure, in which observations (time points) were nested within participants
and participants nested within recruitment site. The mixed and margins commands in Stata version 14
were used to obtain parameter estimates and standard errors (SEs) and the lincom command used to
calculate AUC for each group.27 AUCs associated with the two treatment groups were tested using a
t-test.
Health economic analysis plan
The following sections summarise the health economics analysis plan, with full details provided in Chapter 4.
METHODS
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Objectives
The economic evaluation was designed to estimate the costs of resource inputs and quality-adjusted
life-year (QALY) profiles of each trial participant over the 12-month time horizon of the trial, allowing
mean differences in costs and QALYs to be compared between the two arms of the trial. The primary
objective was to evaluate the incremental cost-effectiveness of extra-articular distal tibia fractures treated
with IM nail fixation versus locking plate fixation and to provide an estimate of the incremental net benefit.
Measurement of outcomes
Health-related quality of life was estimated using responses from the EQ-5D. This instrument facilitates the
generation of a utility score from a person’s health-related quality of life. A health utility score refers to the
preference that individuals have for any particular set of health outcomes. Patients completed the EQ-5D
questionnaire at baseline and at 3, 6 and 12 months after randomisation, thus providing values of their
health status at the time of questionnaire completion. Patients self-completed an additional EQ-5D at
baseline, which assessed their pre-injury health-related quality of life. The standard UK (York A1) tariff
values were applied to these responses at each time point to obtain utility scores.29 The York A1 tariff
set was derived from a survey of the UK general population (n = 3337), which used the time trade-off
valuation method to estimate utility scores for a subset of 45 EQ-5D health states, with the remainder of
the EQ-5D health states subsequently valued through the estimation of a multivariate model.29 Resulting
utility scores ranged from –0.59 to 1.0, with 0 representing death and 1.0 representing full health; values
below 0 indicate health states worse than death. The second measurement component of the EQ-5D
consists of a 20-cm vertical visual analogue scale (VAS) ranging from 100 (best imaginable health state) to
0 (worst imaginable health state), which provides an indication of the participant’s own assessment of their
health status on the day of the survey. QALYs, which formed the main outcome of the economic analysis,
were calculated using the AUC approach, assuming liner interpolation between the utility measurements.
A five-level version of the EQ-5D (EuroQol-5 Dimensions, five-level version; EQ-5D-5L) was newly available
at the start of the trial, but a UK tariff set for this version of the measure had not yet been published.
Consequently, on advice from the TSC, it was decided to measure health-related quality-of-life outcomes
using the EQ-5D.
Measurement of costs
Total costs for the two intervention arms were estimated by combining (1) resources used during the
operation (implants and consumables), (2) total costs for the inpatient hospital stay and (3) patient-
reported data on resource usage at 3, 6 and 12 months post randomisation. For the 3-month data, the
recall period covered the period following hospital discharge; however, the recall period at subsequent
time points covered the period since the last questionnaire was due to be completed. The trial participant
questionnaires provided information on broader NHS and Personal Social Services (PSS) resource use as a
result of the fracture. Specifically, the questionnaires captured the frequency of use of community-based
health and social care services, number and duration of admissions to inpatient wards [classified as
orthopaedics (your leg), orthopaedics (any bones), rehabilitation unit], number of diagnostic tests, use of
outpatient services (classified as orthopaedics, physiotherapy, emergency department), medication use,
and use of aids and adaptations. PSS included number of weeks of frozen/hot Meals on Wheels, laundry
services and number of visits of carers and social workers. Total costs of resource usage were estimated by
combining the unit cost data for each service with the resource usage data. In addition, the questionnaires
captured private costs incurred by the patient as a result of the fracture, such as private physiotherapy.
Productivity losses and lost income were also captured.
Cost-effectiveness analytical methods
An incremental cost-effectiveness analysis was performed, expressed in terms of incremental cost per QALY
gained. Multiple imputation methods were used to impute missing data and avoid biases associated with
complete-case analysis. The results of the economic evaluation were expressed in terms of incremental cost
per QALY gained. A series of sensitivity analyses was undertaken to explore the implications of uncertainty
on the incremental cost-effectiveness ratios (ICERs). Heterogeneity of cost-effectiveness results was
addressed through the use of subgroup analysis. Further details are provided in Chapter 4.
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Reporting
The reporting of the health economic evaluation is consistent with the Consolidated Health Economic
Evaluation Reporting Standard statement.30
Ethics approval and monitoring
Standard NHS cover for negligent harm was in place. There was no cover for non-negligent harm.
Ethics committee approval
The UK FixDT trial was approved by the Coventry and Warwickshire REC on 6 November 2012 (REC
reference number 12/WM/0340) and by the research and development department of each participating
centre. The final, approved, study protocol has been published.1
Trial Management Group
The day-to-day management of the trial was the responsibility of the trial co-ordinator, who was based at
WCTU and supported by the administrative staff. This management was overseen by the Trial Management
Group (TMG), which met monthly to assess progress. It was also the responsibility of the trial co-ordinator
to undertake training of the research associates at each of the trial centres. The trial statistician and health
economist were closely involved in the setting up of data-capture systems and the design of databases and
clinical reporting forms.
Trial Steering Committee
A TSC was responsible for monitoring and supervising the progress of the UK FixDT trial. The TSC consisted
of independent experts, a lay member and the chief investigator on behalf of the TMG. Membership of the
TSC is given in Acknowledgements.
Data Monitoring Committee
The DMC was independent of the trial and was tasked with monitoring ethics, safety and data integrity.
The trial statistician provided the data and analyses requested by the DMC at each of the meetings.
Membership of the DMC is given in Acknowledgements.
Patient and public involvement
Before the pilot study that led to the UK FixDT trial, an informal survey was conducted at a large university
hospital trust to establish the opinion of patients and their carers with regard to research in orthopaedic
trauma. We established that patients place great importance on research comparing different types of
interventions in the area of trauma surgery. Furthermore, patients have demonstrated that they are willing
to take part in such trials.
The opinions of patients regarding the interventions and the trial procedures were reviewed during the
pilot study16 and informed the design of the UK FixDT trial and, specifically, the patient-facing materials.
Independent lay representation was present on the TSC. Members of the trauma patient and public
involvement group also reviewed the progress of the UK FixDT trial at the annual National Institute for
Health Research (NIHR) trauma trials meetings.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
16
Chapter 3 Results
Screening and recruitment
Screening
Screening for potential participants began in April 2013. In total, 2118 patients with a tibial fracture were
screened over 36 months. Screening data are presented to help assess the generalisability of the results to
the overall population. Screening data are presented for all sites, with the exception of the Edinburgh site,
which was closed to recruitment early in the main phase of the study.
There were significant differences in the total number of potential participants who were assessed
between recruiting sites because of the varying practice at each site; for example, some sites screened
children aged < 16 years but other sites were adult-only trauma centres. The wide variation in totals by
centre indicates that some sites screened extensively and recorded any patient with a fracture involving the
tibia; however, others appear to have only recorded fractures of the distal tibia on the screening logs.
The reasons why screened patients were not eligible (n = 1581) are detailed in Table 27, Appendix 1.
The most common reasons for participant ineligibility were that the fracture did not extend to within
2 Müller squares of the ankle joint (375/1581; 24%), the fracture was open (369/1581; 23%) and the
fracture extended into the ankle joint (329/1581; 21%).
The total number of potentially eligible patients for the study was 537. The reasons why potentially eligible
patients were not randomised (n = 216) are given in Table 28, Appendix 1.
Of the 537 eligible potential participants identified on screening logs, 40% (216/537) were not randomised.
The conversion rate of eligible potential participants to randomised participants was therefore 60%. The
most common reasons for non-participation were that there were no research staff available to consent the
patient (n = 53; 25%) or that the surgeon had a preference to use an IM nail (n = 54; 25%). The other
common reason was that the patient did not want to be part of a research study (n = 25; 12%). There were
18 potential participants for whom the reason for non-participation was ‘other’; these reasons included skin
around ankle precluded plate fixation (n = 4), primary amputation (n = 3) and hind foot nail used (n = 2).
The complete table of reasons why eligible potential participants were not randomised, by site, is given in
Table 28, Appendix 1.
Data on sex and age were available for almost all of the patients screened (2003/2118; 95%). The largest
subgroup of screened patients were men aged < 50 years, who accounted for 41% (819/2003) of the
screened population.
Table 3 shows the age and sex of potentially eligible participants by randomised status (randomised or not
randomised). The ages of both groups were similar and a t-test comparing the means of both groups showed no
evidence of a difference in age (mean difference –0.9 years, 95% CI –4.1 to 2.3 years). Likewise, a two-sample
test of proportions showed no evidence of a difference in sex distribution between the two groups (p= 0.818).
Recruitment
The trial planned to recruit 320 participants in total. Formal recruitment began in April 2013, with the first
participant being randomised on 22 April 2013 at the lead site, University Hospitals Coventry and Warwickshire
NHS Trust. Recruitment was undertaken at 28 sites over 36 months, with the final participant being randomised
on 3 May 2016. For reporting purposes, the final participant has been included in the April 2016 recruitment
month for ease of presentation. Details of site names and their opening dates are listed in Table 4.
DOI: 10.3310/hta22250 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 25
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Costa et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17
TABLE 3 Characteristics of eligible participants who were randomised and not randomised
Characteristics
Randomisation status
Randomised Not randomised
Age (years)
n 321 216
Mean (SD) 45.1 (16.3) 46.0 (18.5)
Median (IQR) 43.4 (31.6–57.5) 44.8 (30.2–57.5)
Sex, n (%)
Female 124 (39) 80 (37)
Male 197 (61) 130 (60)
Missing 0 (0) 6 (3)
IQR, interquartile range.
TABLE 4 The UK FixDT trial research sites
Number Full name Opening date
1 University Hospitals Coventry & Warwickshire 8 April 2013
2 Addenbrookes Hospital 2 May 2013
3 Frenchay Hospital 12 June 2013
4 University Hospitals of Leicester 16 July 2013
5 Nottingham University Hospitals 25 July 2013
6 James Cook Hospital 5 September 2013
7 John Radcliffe Hospital 20 December 2013
8 Aberdeen Royal Infirmary 14 January 2014
9 Derriford Hospital 15 January 2014
10 Royal Stoke University Hospital 31 January 2014
11 Royal Sussex County Hospital 30 January 2014
12 Royal Infirmary of Edinburgh 16 January 2014
13 Royal Victoria Infirmary 6 February 2014
14 Glasgow Royal Infirmary 11 March 2014
15 Royal Berkshire Hospital 8 May 2014
16 Poole Hospital 13 May 2014
17 Queen Alexandra Hospital 29 May 2014
18 King’s College Hospital 10 June 2014
19 Aintree University Hospital 15 July 2014
20 Southampton General Hospital 4 August 2014
21 University Hospitals of Birmingham 5 August 2014
22 Leeds Teaching Hospital 12 August 2014
23 St George’s Hospital 11 September 2014
24 Hull Royal Infirmary 13 October 2014
25 North Tyneside General Hospital & Wansbeck General 20 November 2014
26 Heartlands Hospital 3 February 2015
27 Sunderland Royal Hospital 26 February 2015
28 Basingstoke & North Hampshire Hospital 10 June 2015
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The pilot phase was completed at the end of November 2013, with six sites open to recruitment. The
planned recruitment rate was 0.75 participants pcpm. The recruitment rate averaged 0.6 participants pcpm
during this phase, so the TSC recommended that the number of sites was increased from 18 to at least 24
to enable the trial to meet the target recruitment of 320 participants within the 30-month recruitment
window. This resulted in a revised target of 0.6 participants pcpm.
Actual recruitment rates, by site, are shown in Table 29, Appendix 1. The overall observed recruitment rate
for the main phase of the trial was 0.47 participants pcpm. This was somewhat lower than the revised
target and so the number of trial sites was further increased to 28. One site was closed after just one
patient was recruited, and screening data are not presented for this site.
Figure 2 illustrates the progression of recruitment over time, towards the required sample size target of 320.
Recruitment slowed towards the end of the planned recruitment phase, so the recruitment window was
extended, although this was still within the original timeline of the trial. Figure 3 shows the Consolidated
Standards of Reporting Trials (CONSORT) flow diagram for the UK FixDT trial.
Table 5 describes the follow-up rates achieved during the trial. The expected follow-up rate used for
sample size adjustment at 6 months was 80%. This was surpassed at the 6-month time point, with 88%
of DRI assessments completed. Similar completion rates of 86% and 80% were achieved at the 3- and
12-month time points, respectively.
Tables 30 and 31, Appendix 1 demonstrate recruitment by stratification variables, namely age group and
centre. There is good balance with respect to each factor, indicating that the minimisation procedure used
to allocate treatment was implemented successfully.
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FIGURE 2 Overall recruitment progression and target recruitment during the main phase (January 2014–April 2016)
of the UK FixDT trial.
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The histograms in Figure 4 show the distribution of age in years, separately by sex. The overlaid kernel
density estimator (the kdensity option of the histogram function in Stata version 14) shows the smoothed
distribution and highlights the differences between sexes, with a noticeable but expected peak in the
number of young male patients randomised. The mean difference in age between men and women was
6.8 years, 95% CI 3.2 to 10.4 years.
Screened and eligible
(n = 537)
Randomised
(n = 321)
IM nail
(n = 161)
IM nail
(n = 156)
Locking plate
(n = 4)
Other treatment
(n = 1)
Withdrawals
(n = 4)
DRI at baseline, n = 160, 99%
DRI at 3 months, n = 134, 83%
DRI at 6 months, n = 143, 89%
DRI at 12 months, n = 128, 80%
• Patient wanted specific treatment, n = 38
• Patient did not want surgery, n = 13
• Patient did not want to be part of a study, n = 25
• Patient did not want to complete questionnaire, n = 9
• Research staff unavailable, n = 53
• Surgeon prefers IM nail, n = 54
• Surgeon prefers locking plate, n = 3
• Other reason, n = 18
• No reason, n = 3
DRI at baseline, n = 158, 99%
DRI at 3 months, n = 142, 89%
DRI at 6 months, n = 141, 88%
DRI at 12 months, n = 130, 81%
Withdrawals
(n = 6)
Locking plate
(n = 160)
Locking plate
(n = 137)
IM nail
(n = 19)
Other treatment
(n = 4)
Allocated
Received
Follow-up
Eligible but not randomised
(n = 216)
FIGURE 3 The Consolidated Standards of Reporting Trials (CONSORT) flow diagram.
TABLE 5 Follow-up status at time points in the UK FixDT trial
Follow-up status
Time point, n (%)
Baseline 3 months 6 months 12 months
Returned questionnaire 318 (99) 276 (86) 284 (88) 258 (80)
Missed questionnaire 3 (1) 41 (13) 29 (9) 49 (15)
Consent withdrawn before time point 0 (0) 3 (1) 6 (2) 8 (3)
Died before time point 0 (0) 1 (< 1) 2 (1) 6 (2)
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Participant characteristics
The baseline demographic and clinical data were collected directly from the participant at site as part of the
baseline participant’s questionnaire. The baseline demographic and clinical characteristics of both treatment
groups are well balanced, as shown by allocated treatment group in Table 6. Baseline patient-reported
outcome measures also showed good balance with similar mean scores being seen across all four outcomes
measures, as expected.
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FIGURE 4 Age distribution of randomised participants by sex. (a) Female; and (b) male.
TABLE 6 Baseline demographic and clinical characteristics of randomised patients by treatment group
Demographic and clinical characteristic
Treatment groupa
IM nail fixation (N= 161) Locking plate (N= 160)
Age (years)
Mean (SD) 44.3 (16.3) 45.8 (16.3)
Median (IQR) 41.3 (30–57) 45.6 (32–58)
Sex, n (%)
Female 65 (40) 59 (37)
Male 96 (60) 101 (63)
Side of fracture, n (%)
Left 67 (42) 75 (47)
Right 93 (58) 84 (53)
Missing 1 (1) 1 (1)
Previous problems on the injured side, n (%)
Yes 40 (25) 36 (23)
No 120 (74) 123 (77)
continued
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TABLE 6 Baseline demographic and clinical characteristics of randomised patients by treatment group (continued )
Demographic and clinical characteristic
Treatment groupa
IM nail fixation (N= 161) Locking plate (N= 160)
Mechanism of injury, n (%)
Low-energy fall 85 (53) 87 (54)
High-energy fall 27 (17) 24 (15)
Road traffic accident 15 (9) 22 (14)
Crush injury 8 (5) 3 (2)
Contact sports injury 14 (9) 11 (7)
Other 11 (7) 12 (8)
Body mass index (kg/m2)
Mean (SD) 27.7 (6.2) 27.7 (6.9)
Median (IQR) 26.5 (23–31) 26.7 (23–30)
Current smoking status
Yes, n (%) 53 (33) 50 (31)
No, n (%) 107 (66) 108 (68)
If yes, for how many years smoking
n 48 40
Mean (SD) 19 (12) 26 (14)
Median (IQR) 18 (10–28) 28 (15–37)
Alcohol consumption (units per week), n (%)
0–7 86 (53) 87 (54)
8–14 28 (17) 24 (15)
15–21 28 (17) 22 (14)
> 21 18 (11) 22 (14)
Diabetes, n (%)
Yes 6 (4) 7 (4)
No 154 (95) 152 (95)
DRI (pre-injury)
Mean (SD) 9.9 (19.0) 10.0 (18.4)
Median (IQR) 1.1 (0–10.6) 1.6 (0–11.5)
OMAS (pre-injury)
Mean (SD) 91.4 (19.0) 94.2 (14.0)
Median (IQR) 100 (95–100) 100 (95–100)
EQ-5D index score (pre-injury)
Mean (SD) 0.860 (0.23) 0.888 (0.21)
Median (IQR) 1 (0.80–1.00) 1 (0.85–1.00)
EQ-5D VAS score (pre-injury)
Mean (SD) 81.5 (17.7) 80.9 (17.5)
Median (IQR) 85 (70–95) 90 (74–90)
IQR, interquartile range.
a When numbers do not total to treatment group, this indicates that data were missing.
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At the baseline assessment, participants were also asked whether or not they had a strong treatment
preference and, if so, for which treatment: 70% (222/321) had no preference; 16% (52/321) preferred IM
nail fixation and 13% (43/321) locking plate fixation, with 1% (4/321) of participants not giving a response.
Interventions
Table 7 provides information on the surgical procedures performed. Table 8 provides further detail specific
to those participants who received an IM nail or locking plate, respectively. Unless otherwise stated, all
further analyses and tables in the remainder of the report will be described on an intention-to-treat basis.
It was of note that the mean duration of the operations was the same for both treatment groups.
TABLE 7 Core operation details summarised by treatment group
Operation details
Treatment groupa
IM nail fixation (N= 161) Locking plate (N= 160)
Intraoperative problems, n (%)
Yes 3 (2) 3 (2)
No 157 (98) 156 (98)
Missing 1 (1) 1 (1)
If yes, what was the problem? (n)
Nerve injury 0 0
Vascular injury 0 1
Tendon injury 0 0
Extension of fracture 3 2
Intra-articular extension of the fracture, n (%)
Yes 7 (4) 3 (2)
No 127 (79) 128 (80)
Missing 27 (17) 29 (18)
Fixation of the fibula, n (%)
Yes 10 (6) 12 (8)
No 150 (93) 146 (91)
Missing 1 (1) 2 (1)
Any other surgery for additional injuries, n (%)
Yes 8 (5) 3 (2)
No 152 (94) 156 (97)
Missing 1 (1) 1 (1)
Lead surgeon grade, n (%)
Consultant 90 (56) 99 (62)
Staff grade/associate specialist 13 (8) 15 (9)
Specialist trainee 50 (31) 41 (26)
Other 7 (4) 4 (3)
Missing 1 (1) 1 (1)
continued
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TABLE 7 Core operation details summarised by treatment group (continued )
Operation details
Treatment groupa
IM nail fixation (N= 161) Locking plate (N= 160)
Total number of surgeons present in theatre
Mean 2.5 2.4
n 159 159
Median 2 2
Missing 2 1
Operation total duration (minutes)
n 158 158
Mean (SD) 124 (43) 124 (44)
Median (IQR) 120 (90–145) 120 (96–151)
IQR, interquartile range.
a When numbers do not total to treatment group, this indicates that data were missing.
TABLE 8 Treatment-specific operation details
Treatment-specific operation detail n (%)
IM nail fixation (n = 174)
Number of bolts used in coronal plane
0 16 (9)
1 50 (29)
2 108 (62)
Missing 0 (0)
Number of bolts used in sagittal plane
0 67 (39)
1 82 (47)
2 25 (14)
Missing 0 (0)
Number of bolts used in oblique plane
0 144 (83)
1 27 (16)
2 2 (1)
Missing 1 (1)
Number of blocking screws used
0 138 (79)
1 31 (18)
2 3 (2)
3 2 (1)
4 0 (0)
Missing 0 (0)
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TABLE 8 Treatment-specific operation details (continued )
Treatment-specific operation detail n (%)
Reduction technique used
Open 12 (7)
Closed 106 (61)
Skeletal traction 20 (11)
No traction 34 (20)
Missing 2 (1)
Surgical approach used
Medial parapatella 69 (40)
Lateral parapatella 0 (0)
Tendon splitting 102 (58)
Suprapatella approach 2 (1)
Missing 1 (1)
Locking plate (n = 142)
Number of locking screws used distal to fracture
1 0 (0)
2 8 (6)
3 24 (17)
4 53 (37)
5 36 (25)
6 16 (11)
> 6 4 (3)
Missing 1 (1)
Number of locking screws used proximal to fracture
0 36 (25)
1 4 (3)
2 16 (11)
3 46 (32)
4 33 (23)
5 7 (5)
> 5 0 (0)
Missing 0 (0)
Number of non-locking screws used distal to fracture
1 60 (42)
2 50 (35)
3 21 (15)
4 6 (4)
5 2 (1)
continued
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Treatment allocation
A total of 91% (293/321) of participants received their allocated treatment (Table 9). Among those
participants allocated to the IM nail fixation group, 97% of whom received their allocated treatment and
in those allocated to the locking plate group, 86% of whom received their allocated treatment. There
were two participant withdrawals before any intervention was undertaken, two were treated with external
fixation only and one was treated with manipulation under anaesthetic only.
In total, there were 28 participants who received a treatment that was not their allocated treatment;
more participants deviated from their allocated treatment in the locking plate group (n = 23) than in the
IM nail fixation group (n = 5). The most common reasons why participants did not receive their allocated
treatment was because of either surgeon choice (n = 10, 36%) or a clinical decision intraoperatively
(n = 13, 46%) (Table 10).
The baseline demographics of patients receiving their allocated treatment were broadly similar to those not
receiving allocated treatment, with mean age 45 versus 47 years, although patients who did not receive
their allocated treatment were more likely to be male (75%).
TABLE 8 Treatment-specific operation details (continued )
Treatment-specific operation detail n (%)
6 2 (1)
> 6 1 (1)
Missing 0 (0)
Number of non-locking screws used proximal to fracture
0 43 (30)
1 38 (27)
2 17 (12)
3 19 (13)
4 21 (15)
5 4 (3)
> 5 0 (0)
Missing 0 (0)
Reduction technique used
Open 73 (51)
Closed 53 (37)
Skeletal traction 11 (8)
No traction 5 (4)
Missing 0 (0)
Surgical approach used
Longitudinal over medial malleolus 93 (65)
Other 49 (35)
Missing 0 (0)
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Outcomes
Primary outcome
Figure 5a shows the trend in group DRI score means over the trial. Figure 5b shows the distribution of the
DRI score at each time point, in which the middle bar is the median, the box represents the interquartile
range and the whiskers extend to 1.5 times the interquartile range, with observations outside this range
presented individually. Figure 5b demonstrates there is a treatment group difference in favour of the IM
nail fixation group at 3 months, but this is reduced and not statistically significant at the 6-month time
point and decreases further at the 12-month time point. Model assumptions were checked and appeared
to be appropriate.
Table 11 shows the treatment estimates modelled using mixed-effects linear regression model, as previously
described. The adjusted estimate of the treatment effect for the DRI score, at the 6-month post randomisation
time point based on an intention-to-treat analysis, is 4.0 points (95% CI –1.0 to 9.0 points) in favour of the
IM nail fixation group compared with the locking plate group. The p-value of 0.114 indicates that there is no
evidence for a statistically significant difference in the DRI score between the two treatment groups at the
6-month post-randomisation time point. The prespecified MCID for the DRI is 8 points; therefore, at the
6-month time point we conclude that if there is a difference in the disability outcomes of the two groups,
it is likely to be appropriately small as to be clinically unimportant. However, the 95% CI does include the
prespecified MCID.
The adjusted estimate of the treatment effect at 3 months is 8.8 (95% CI 4.3 to 13.2) in favour of the
IM nail fixation group compared with the locking plate group. The p-value of < 0.001 indicates that there
is strong evidence for a statistically significant difference in treatment group means at 3 months. The
estimated treatment effect is larger than the prespecified MCID for the DRI of 8 points, so this difference is
likely to be clinically important to patients. At the 12-month time point, the p-value of 0.468 indicates that
TABLE 9 Treatment allocation by treatment received
Received
Allocated (n)
IM nail fixation Locking plate Total
IM nail fixation 156 19 175
Locking plate 4 137 141
Other 1 4 5
Total 161 160 321
TABLE 10 Reasons why allocated treatment not received by treatment group
Reason
Allocated (n)
IM nail fixation Locking plate Total
Surgeon choice 3 7 10
Clinical decision intraoperatively 1 12 13
Lack of equipment 0 2 2
Patient choice 0 1 1
Withdrawal from trial before treatment 1 1 2
Total 5 23 28
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FIGURE 5 The DRI. (a) Box plots of baseline and follow-up scores; and (b) overall trend in means and 95% CIs.
TABLE 11 Disability Rating Index: summary statistics, unadjusted and adjusted treatment effects at all time points
Time point (months)
Treatment group
Difference (95% CI)
p-value
IM nail fixation Locking plate
Mean (SD) n Mean (SD) n Raw Adjusteda
3 44.2 (19.9) 132 52.6 (19.9) 141 8.4 8.8 (4.3 to 13.2) < 0.001
6 29.8 (23.1) 142 33.8 (24.7) 140 4.0 4.0 (–1.0 to 9.0) 0.114
12 23.1 (23.3) 125 24.0 (24.6) 129 0.9 1.9 (–3.2 to 6.9) 0.468
a Mixed-effects regression model based on intention-to-treat analysis approach with allocated treatment group, age
group, baseline pre-injury score and sex as fixed effects, and recruiting site as a random effect.
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there is no evidence for a statistically significant difference in the DRI score between the two treatment
groups at the 12-month post-randomisation time point, and the adjusted treatment difference is 1.9 points
(95% CI 3.2 to 6.9 points) in favour of the IM nail fixation group compared with the locking plate group.
Secondary outcomes
Olerud–Molander Ankle Score questionnaire
The adjusted estimate of the treatment effect for the OMAS, at the 6-month post-randomisation time
point based on an intention-to-treat analysis, is –6.0 points (95% CI –11.2 to –0.7 points) in favour of the
IM nail fixation group compared with the locking plate group (Figure 6 and Table 12). The p-value of
0.026 indicates that there is evidence for a statistically significant difference in the OMAS between the
two treatment groups at the 6-month time point.
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FIGURE 6 The OMAS questionnaire. (a) Box plots of baseline and follow-up scores; and (b) overall trend in means
and 95% CIs.
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EuroQol-5 Dimensions index score
The adjusted estimate of the treatment effect for the EQ-5D index score, at the 6-month post-randomisation
time point based on an intention-to-treat analysis, is –0.063 points (95% CI –0.12 to –0.01 points) in favour
of the IM nail fixation group compared with the locking plate group (Figure 7 and see Table 12). The p-value
of 0.033 indicates that there is evidence for a statistically significant difference in the EQ-5D score between
the two treatment groups at the 6-month time point.
EuroQol-5 Dimensions visual analogue scale score
The adjusted estimate of the treatment effect for the EQ-5D VAS score, at the 6-month post-randomisation
time point based on an intention-to-treat analysis, is –2.5 (95% CI –6.8 to 1.8) in favour of the IM nail
fixation group compared with the locking plate group (Figure 8 and see Table 12). The p-value of 0.247
indicates that there is no evidence of a statistically significant difference in the EQ-5D VAS score between
the two treatment groups at the 6-month time point.
Per-treatment analysis
Table 13 shows the results of per-treatment analyses, in which participants were analysed in per-treatment
groups, that is, those who received IM nails compared with those who received locking plates. The five
participants who did not receive either treatment were excluded from these analyses. An adjusted per-
treatment analysis of the DRI scores at 6 months gave an adjusted treatment effect of 4.2 (95% CI –0.9
to 9.2) and a p-value equal to 0.103. Adjusted analysis at 3 and 12 months also gave similar results to the
intention-to-treat analysis in Primary outcome.
Adjusted per-treatment analysis of the secondary outcome measures are also given in Table 13. All analyses
yielded similar results to the equivalent intention-to-treat analysis.
TABLE 12 Secondary patient-reported outcome measures: summary statistics, unadjusted and adjusted treatment
effects at all time points
Outcome
measure,
time point
Treatment group
Difference (95% CI)
p-value
IM nail fixation Locking plate
Mean (SD) n Mean (SD) n Raw Adjusteda
OMAS (points)
3 months 42.3 (22.1) 130 36.0 (21.3) 139 –6.3 –7.0 (–12.0 to –2.0) 0.006
6 months 62.4 (23.1) 139 57.6 (24.9) 135 –4.9 –6.0 (–11.2 to –0.7) 0.026
12 months 73.8 (22.5) 20 70.8 (24.2) 29 –3.0 –3.6 (–9.1 to 1.9) 0.195
EQ-5D index score
Post injury –0.003 (0.334) 158 –0.024 (0.311) 156 –0.021 –0.030 (–0.09 to 0.03) 0.331
3 months 0.546 (0.273) 134 0.499 (0.302) 142 –0.047 –0.058 (–0.12 to 0.00) 0.067
6 months 0.670 (0.265) 143 0.622 (0.275) 141 –0.048 –0.064 (–0.12 to –0.01) 0.029
12 months 0.722 (0.278) 128 0.731 (0.246) 130 0.009 –0.018 (–0.07 to 0.05) 0.525
EQ-5D VAS score
Post injury 46.6 (24.5) 158 45.3 (24.8) 157 –1.3 –0.8 (–5.7 to 4.0) 0.735
3 months 66.7 (20.5) 134 64.4 (21.1) 142 –2.3 –1.9 (–6.4 to 2.6) 0.418
6 months 75.0 (19.6) 143 71.6 (21.2) 141 –3.4 –2.5 (–6.8 to 1.8) 0.247
12 months 78.3 (20.5) 128 78.4 (20.8) 129 0.1 –0.2 (–4.6 to 4.2) 0.935
a Mixed-effects regression model based on intention-to-treat analysis approach with allocated treatment group, age
group, baseline pre-injury score and sex as fixed effects, and recruiting site as a random effect.
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Missing outcome data
The follow-up questionnaire completion rate was very good at all time points of the UK FixDT study.
The expected loss to follow-up rate at the 6-month primary outcome time point was 20%; the actual
rate was 12%. A summary of status at each follow-up time point is given in Table 5. In total, 284 out of
321 participants (88.4%) completed a DRI at the 6-month time point. The item-level missingness for the
DRI score, and the secondary outcome measures, is given in Tables 32–34, Appendix 2. There were very
few missing items in the DRI questionnaire at baseline (one item from 3816 items; < 0.1%), 3 months
(1/3312; < 0.1%), 6 months (2/3408; < 0.1%) and 12 months (5/2640; 0.2%). Similar levels of missing
data were seen across the OMAS questionnaire and the EQ-5D, with item-level missingness below 0.2%
for all scales.
Table 14 shows the impact that including partial completion of the DRI using 11 or fewer items had on
calculating the overall DRI score. There is very little difference in the adjusted treatment differences compared
with the results given in Primary outcome based on fully completed questionnaires only. The largest differences
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FIGURE 7 The EQ-5D index. (a) Box plots of baseline and follow-up scores; and (b) overall trend in means and 95% CIs.
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are seen in the 12-month questionnaire data but this is because there are fewer observations and marginally
more missing items than at 3- and 6-month data collection, resulting in a slightly larger treatment difference but
being still in favour of IM nail fixation, as per the results in Primary outcome.
Subgroup analysis
At 6 months, the p-value of 0.516 indicates that there is no evidence for a significant interaction effect
between age group and treatment group. The results of this analysis, and the subgroup analyses performed
at 3 and 12 months, are given in Table 15.
Neither was there any evidence for a significant interaction effect between sex and treatment group (p-value
of the interaction term = 0.384).
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TABLE 13 Means and SDs of outcomes at all time points and estimated treatment effects after adjustment, using a
per-treatment analysis approach
Outcome measure,
time point
Treatment group
Difference (95% CI)
p-value
IM nail fixation Locking plate
Mean (SD) n Mean (SD) n Raw Adjusteda
DRI score (points)
3 months 44.5 (20.8) 148 53.2 (18.9) 123 8.7 9.0 (4.5 to 13.5) < 0.001
6 months 29.9 (23.4) 154 34.3 (24.6) 126 4.5 4.2 (–0.9 to 9.2) 0.103
12 months 23.5 (23.5) 136 24.0 (24.5) 116 0.5 0.9 (–4.2 to 6.0) 0.727
OMAS (points)
3 months 42.1 (23.1) 144 35.3 (19.9) 123 –6.8 –7.2 (–12.3 to –2.2) 0.005
6 months 61.9 (23.8) 150 57.5 (24.5) 122 –4.5 –4.9 (–10.2 to 0.4) 0.073
12 months 73.2 (23.2) 129 70.8 (23.7) 118 –2.3 –2.4 (–7.9 to 3.1) 0.395
EQ-5D index score
3 months 0.533 (0.30) 150 0.507 (0.28) 124 –0.025 –0.046 (–0.11 to 0.02) 0.158
6 months 0.672 (0.27) 155 0.614 (0.28) 127 –0.058 –0.067 (–0.12 to –0.01) 0.023
12 months 0.718 (0.28) 138 0.732 (0.24) 118 0.014 –0.004 (–0.06 to 0.05) 0.900
EQ-5D VAS score
3 months 66.5 (20.6) 150 64.5 (21.2) 124 –2.0 –2.0 (–6.5 to 2.6) 0.399
6 months 75.0 (19.9) 155 71.2 (21.1) 127 –3.7 –2.5 (–6.8 to 1.8) 0.254
12 months 78.1 (20.9) 137 78.4 (20.5) 118 0.3 0.6 (–3.9 to 5.0) 0.803
a Mixed-effects regression model based on an intention-to-treat analysis approach with allocated treatment group, age
group, baseline pre-injury score and sex as fixed effects, and recruiting site as a random effect.
TABLE 14 Means and SDs of outcome at all time points and estimated treatment effects after adjustment per
treatment, using all values
Outcome measure,
time point
Treatment group
Difference (95% CI)
p-value
IM nail fixation Locking plate
Mean (SD) n Mean (SD) n Raw Adjusted
DRI score (points)
3 months 44.2 (20.1) 134 52.7 (19.9) 142 8.5 8.7 (4.2 to 13.2) < 0.001
6 months 30.0 (23.0) 143 33.9 (24.6) 141 3.9 4.0 (–1.0 to 8.9) 0.119
12 months 22.8 (23.1) 127 24.1 (24.6) 130 1.3 2.2 (–2.8 to 7.2) 0.386
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Exploratory analyses
Area under the curve analysis for the Disability Rating Index score
To complement the preplanned analysis, a post hoc exploratory analysis using DRI score at all four time
points was conducted. This analysis simplified longitudinal data collected at four time points to a single
value, namely the AUC, and facilitated comparisons of the AUCs between treatment groups.
The group-specific time point means were used to calculate AUCs for treatment groups, as described in
the Methods. Using the predicted model parameter, the calculated AUC for those participants who were
allocated to the IM nail fixation group was 350 (SE 16.4) and for the locking plate group was 407 (SE 16.3),
yielding a between-group difference of 57, 95% CI 12 to 103. Larger DRI scores represent higher levels of
disability; therefore, larger AUCs are also associated with increased levels of disability. A t-test comparing
the values between groups yielded a p-value of 0.013, indicating that there is a statistically significant
difference in AUC between treatment groups. Clinically, this result may be interpreted as evidence that
those allocated to locking plates experienced more disability over the 12-month trial follow-up period than
those allocated to the IM nail fixation.
Complications
Local complications related to the fracture or its treatment
Complications were assessed by the research team at the 6-week time point for almost all randomised
participants (n = 314; 99% of participants who had a surgical procedure) and, again, in the patient
reported questionnaires at 3, 6 and 12 months. Table 16 shows these complications by allocated
treatment group.
The number of patients with symptoms related to infection was higher in the locking plate group (n = 32;
20%) than in the nail fixation group (n = 20; 13%), although this was not statistically significant (Fisher’s
exact test p = 0.094). Twenty-one (13%) patients in the locking plate group and 14 (9%) in the IM nail
fixation group were treated with antibiotics.
TABLE 15 Results of subgroup analysis of the DRI score showing means and SDs of outcome at all time points and
estimated treatment effects after adjustment
Time point, age (years)
Treatment group
Difference (95% CI)
p-valueb
IM nail fixation Locking plate
Mean (SD) n Mean (SD) n Raw Adjusteda
3 months
< 50 41.3 (19.4) 76 51.5 (19.6) 84 10.2 10.8 (4.9 to 16.6) 0.290
≥ 50 48.2 (20.2) 56 54.2 (20.5) 57 6.0 5.9 (–1.1 to 12.8)
6 months
< 50 25.6 (21.8) 84 31.1 (24.5) 87 5.5 5.4 (–1.0 to 11.8) 0.516
≥ 50 35.9 (23.7) 58 38.2 (24.6) 53 2.3 2.0 (–6.0 to 10.0)
12 months
< 50 18.6 (22.6) 71 21.8 (22.8) 79 3.2 3.4 (–3.1 to 10.0) 0.465
≥ 50 28.8 (23.0) 54 27.4 (27.3) 50 –1.5 –0.4 (–8.3 to 7.5)
a Mixed-effects regression model based on intention-to-treat analysis approach with allocated treatment group, age
group, baseline pre-injury score and sex as fixed effects, and recruiting site as a random effect.
b p-values are of the interaction term between the variable of interest and treatment in the model.
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TABLE 16 Local complications
Complication
Treatment group
p-valueaIM nail fixation (n= 157) Locking plate (n= 157)
Any infection symptoms identified, n (%)
Yes 20 (13) 32 (20) 0.094
No 137 (87) 125 (80)
Which symptoms?b
Erythema 16 27
Persistent serous drainage 4 12
Purulent drainage 4 6
Dehiscence 2 8
Treated with antibiotics, n (%)
Yes 14 (9) 21 (13) 0.209
No 143 (91) 136 (87)
Neurological injury, n (%)
Yes 8 (5) 4 (3) 0.378
No 149 (93) 153 (96)
Vascular injury, n (%)
Yes 1 (1) 0 (0) 1.000
No 156 (97) 157 (98)
Tendon injury, n (%)
Yes 0 (0) 2 (1) 0.498
No 157 (98) 155 (97)
Complex regional pain syndrome, n (%)
Yes 0 (0) 1 (1) 1.000
No 157 (98) 155 (98)
Deep-vein thrombosis (within 6 weeks), n (%)
Yes 1 (1) 2 (1) 1.000
No 156 (97) 155 (97)
Pulmonary embolism (within 6 weeks), n (%)
Yes 1 (1) 0 (0) 1.000
No 156 (97) 157 (98)
Patient fully weight-bearing, n (%)
Yes 53 (33) 23 (14) < 0.001
No 104 (65) 134 (84)
Missing 4 (2) 3 (2)
a p-values based on Fisher’s exact test.
b Multiple symptoms could be selected, so count of symptoms is not equal to total number of infections.
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Other local complications were rare in both groups.
Data on ability/inability to bear weight on the injured leg were also collected at the 6-week visit in Table 16.
In total, 33% of those allocated to nail fixation reported being fully weight-bearing at the 6-week visit,
compared with only 14% of those allocated to locking plates. The difference in proportions is 0.19, 95% CI
0.10 to 0.41. The p-value for the difference is these proportions is p < 0.001, indicating strong evidence of
a difference in the proportion of participants weight-bearing at 6 weeks.
Further surgery related to the fracture or its treatment is shown in Table 17. Where patients reported any
further surgery, full details of the operation were requested and provided from the treating centre. There
was more further surgery in the locking plate group (n = 19; 12%) than in the nail fixation group (n = 14;
9%), although this was not statistically significant (Fisher’s exact test p-value = 0.363).
Radiographic outcomes
An independent orthopaedic surgeon assessed the radiographic images, when available. The results of
these independent assessments are given in Tables 18 and 19 for 6-week and 12-month images,
respectively.
In addition to the independently assessed radiographs, the principal investigator at each recruiting site
assessed key radiographic outcomes and reported these on the 6-week postoperative form. Comparisons
between these site assessments and independent assessments were investigated, and there were good
levels of agreement between assessors.
TABLE 17 Further related surgery within 12 months of injury
Surgical procedure
Treatment group
p-valueaIM nail fixation (n= 161) Locking plate (n= 160)
Any additional surgical procedure on trial distal tibia, n (%)
Yes 14 (9) 19 (12) 0.363
No 148 (92) 141 (88)
If so, which procedure?,b n (%)
Metalwork removal
Yes 11 (7) 14 (9) 0.540
No 150 (93) 146 (146)
Surgical debridement
Yes 1 (1) 5 (3) 0.121
No 160 (99) 155 (97)
Revision of internal fixation
Yes 2 (1) 5 (3) 0.283
No 159 (99) 155 (97)
Other operative procedure
Yes 4 (2) 3 (2) 1.000
No 157 (98) 157 (98)
a p-values are for Fisher’s exact test.
b Multiple procedures may occur during one operation, so totals do not equal first row, which counts participants and not
procedures.
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TABLE 18 Imaging outcomes at the 6-week post-surgery radiograph
Deformity
Trial group, n (%)
p-valueaIM nail fixation Locking plate
Lateral deformity (> 5°)
Yes 5 (3) 5 (2) 1.000
No 135 (84) 140 (88)
Missing 21 (13) 15 (10)
Anteroposterior deformity (> 10°)
Yes 12 (7) 5 (3) 0.081
No 128 (80) 142 (89)
Missing 21 (13) 13 (8)
Shortening (> 10mm)
Yes 5 (3) 0 (0) 0.028
No 136 (84) 146 (91)
Missing 20 (13) 14 (9)
a The p-values are from Fisher’s exact tests.
TABLE 19 Imaging outcomes at the 12-month post-surgery radiograph
Deformity
Treatment group, n (%)
p-valueaIM nail fixation Locking plate
Lateral deformity (> 5°)
Yes 1 (1) 0 (0) 0.469
No 82 (51) 94 (59)
Missing 78 (48) 66 (41)
Anteroposterior deformity (> 10°)
Yes 11 (7) 8 (5) 0.339
No 72 (45) 86 (54)
Missing 78 (48) 66 (41)
Shortening (> 10mm)
Yes 0 (0) 0 (0) 1.000
No 83 (52) 94 (59)
Missing 78 (48) 66 (41)
Ankle osteoarthritis
Yes 10 (6) 7 (4) 0.320
No 73 (45) 87 (54)
Missing 78 (48) 66 (41)
a The p-values are from Fisher’s exact tests.
DOI: 10.3310/hta22250 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 25
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Costa et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
37
Systemic complications potentially related to the fracture or its treatment
Information regarding complications was also given through the SAE reporting pathway over the full
12 months of the trial. Data from related SAEs have been included in these complication profiles, with
cross-referencing to ensure that appropriate counts are taken using multiple data sources. Not all of the
venous thromboses or infections of the chest, urinary system, etc., will be related to the treatment but
we have included all ‘potentially’ related events here for completeness. These data are summarised by
treatment group in Tables 17 and 20.
Serious adverse event unrelated to the fracture or its treatment
There was a total of 126 unrelated SAEs, which were reported by 83 participants. ‘Relatedness’ was
assessed by the principal investigator at each centre. In total, 60 participants reported only one SAE,
14 reported two SAEs and nine reported more than two SAEs. The maximum number of unique SAE
reports by a participant was nine. The reasons for SAE reporting are given in Table 21, by treatment group.
More than one reason can be selected for each report of a SAE (e.g. both hospitalisation and persistent
disability may be reasons); therefore, for reporting purposes, the most severe reason is presented.
TABLE 20 Systemic complications
Complication
Treatment group, n (%)
p-valueaIM nail fixation (n= 161) Locking plate (n= 160)
Deep-vein thrombosis
Yes 7 (4) 6 (4) 1.000
No 154 (96) 15 (96)
Infection treated with antibiotics (not wound related)
Yes 24 (15) 31 (19) 0.303
No 137 (85) 129 (81)
a p-values based on Fisher’s exact test.
TABLE 21 Serious adverse event reporting classifications by treatment arm
Reason
Treatment group (n)
TotalIM nail fixation Locking plate
Death 2 4 6
Life-threatening condition 0 3 3
Hospitalisation or prolongation of existing hospitalisation 24 47 71
Persistent disability/incapacity 1 1 2
Required medical intervention to prevent one of above 11 15 26
Otherwise medically significant 8 10 18
Total 46 80 126
RESULTS
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Chapter 4 Economic evaluation
Methods
Aim and perspective
The main objective of the health economic evaluation was to assess the cost-effectiveness of treating
displaced extra-articular fractures of the distal tibia using IM nail fixation versus locking plate fixation.
The primary analysis was undertaken from the perspective of the NHS and PSS, as recommended by the
National Institute for Health and Care Excellence (NICE).31 A societal perspective for costs was adopted for
the sensitivity analysis and this included private costs incurred by trial participants and their families, as well
as productivity losses and loss of earnings as a result of work absences.
The primary health economic outcome was the ICER attributable to IM nail fixation, which was calculated as
the incremental cost per QALY gained 12 months after randomisation. No discounting of costs or health
consequences was required as the trial-based economic evaluation was limited to a 12-month time horizon.
Measurement of resource use and costs
A comprehensive strategy was adopted to estimate the costs associated with distal tibia fixation using either
locking plate or IM nail fixation. This included the (1) estimation of the initial fixation surgery costs and
(2) estimation of broader health and personal social service resource inputs and broader societal resource
inputs. All costs were expressed in pounds sterling and valued in 2014–15 prices. When appropriate, costs
were inflated or deflated to 2014–15 prices using the Hospital and Community Health Services (HCHS)
Pay and Price Inflation.32
Costing of distal tibia fixation
The initial fixation surgery costs (intervention costs) were based on the initial hospital stay and associated
operative costs, as reported in Table 22. The cost of distal tibia fracture fixation surgery was estimated using
the NHS reference costs, specifically Healthcare Resource Group (HRG) code HT23D (major knee procedures
for trauma).33 According to this HRG code, operative costs for distal tibia fixation were £5315.47 for cases
with a mean length of hospital stay of 5 days. Patient-specific costs for the initial operative period were
identified using the average length of stay following primary surgery, as reported in the patient records.
The mean length of hospital stay was 3.87 days for IM nail fixation versus 3.85 days for locking plate fixation
and SEs were 0.34 and 0.33 days, respectively. The surgery cost of patients who stayed longer than 5 days
was adjusted using the cost per excess bed-day figure of £327.00 for the same HRG code. For patients who
stayed in hospitals < 5 days, we assumed that treatment costs were disproportionately weighted towards the
first 3 days of each initial hospital admission. Thus, the cost to the NHS of a patient who stayed in hospital
for 3 days was calculated as £5315.47 – (2 × £327), that is, the 5-day tariff minus the bed-day cost of £327
per each day not spent in hospital.
In addition, operative costs included the implants used during the surgery, namely nails, plates, locking
screws/bolts, blocking screws and non-locking screws. Estimation of the number of each of these implants
used involved prospectively recording the number of items used for each patient from the operation notes
and radiographs. The total cost of implants for each patient was calculated by combining the resource
inputs with their unit cost values; the unit cost values were derived from NHS trust finance departments.
Measuring broader resource use
Individual-level data on all significant health and personal social service and broader societal resource
inputs were collected during the trial using follow-up questionnaires completed by trial participants. These
data were collected at 3, 6 and 12 months post randomisation. The questionnaires captured the number
and duration of admissions to inpatient hospital wards by ward type, number and type of diagnostic tests,
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use and type of outpatient hospital services, frequency of use and type of community-based health and
social care services, medication use and aids and devices provided. In addition, the questionnaires captured
the direct non-medical costs (including travel expenses) incurred by patients and their carers, as well as
number of days off work and gross loss of earnings, attributable to the trial participant’s health state or
contacts with care providers. Copies of the resource use questionnaires administered at each time point
are provided in Appendix 3.
Valuation of resource use
The derivation of unit cost values was consistent with NICE’s Guide to the Methods of Technology Appraisal
201331 and included values extracted from the Department of Health and Social Care’s Reference Costs
2014–15,33 the Personal Social Services Research Unit (PSSRU)’s Unit Costs of Health and Social Care 2015,34
NHS Prescription Cost Analysis and the British National Formulary.35 Table 35, Appendix 4, summarises the
unit cost values and data sources for the broader resource use categories.
Further inpatient admissions following the initial operation were costed as minor knee procedures for
non-trauma (HRG code HN25A) if the inpatient care involved procedures of the leg. However, if the inpatient
admission was related to a surgical complication of the primary surgery, individual HRG codes that related to
TABLE 22 Unit costs associated with initial operative procedures and initial hospital stay for IM nail and locking
plate fixation
Item Unit cost (£) Source
Surgery costsa
Average surgery cost of distal tibia fracture
fixation (based on a mean length of stay of
5 daysb)
5315.47 Reference Costs 2014–15, ‘major knee
procedures for trauma, 19 years and
over, with a CC score of 0’, HT23D33
Cost per excess bed-day 327.00 Reference Costs 2014–15, ‘major knee
procedures for trauma, 19 years and
over, with a CC score of 0’, HT23D33
Implants: IM nail fixation
Guide wire 3.2 × 300 43.11 UHCW finance department
Reaming rod 2.5 × 1000 63.47 UHCW finance department
Distal bolts 45.88 UHCW finance department
End cap 37.93 UHCW finance department
Blocking screw 29.80 UHCW finance department
Nail 265.53 UHCW finance department
Implants: locking plate fixation
Medial distal tibia plate 358.41 UHCW finance department
Anterolateral distal tibia plate 412.81 UHCW finance department
Lock screw (3.5-mm diameter) 37.79 UHCW finance department
Lock screw (2.7-mm diameter) 26.79 UHCW finance department
Non-lock screw (3.5-mm diameter) 6.98 UHCW finance department
Non-lock screw (2.7-mm diameter) 14.00 UHCW finance department
CC, complications and comorbidities; UHCW, University Hospitals Coventry and Warwick NHS Trust.
a HRG code for distal tibia fracture fixation is similar for both IM and locking plate fixation.
b Surgery cost from Reference Costs 2014–1533 is based on assumed mean length of stay of 5 days for this category of
patients; adjustments were made for all patients who stayed in hospital for a period less than 5 days; detailed
methodology is explained in Valuation of resource use.
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the subsequent operation procedures undertaken (e.g. debridement, metalwork removal, revision of internal
fixation) were derived using the NHS HRG4 2014/15 Reference Cost Grouper software version RC1415
(NHS Digital, Leeds, UK). The Department of Health and Social Care’s Reference Costs 2014–1533 was used
to assign the costs for each of the derived HRG codes. Subsequent inpatient care that was unrelated to
procedures of the leg were also costed using Reference Costs 2014–1533 (Table 35, Appendix 4). The same
approach was taken to cost subsequent hospital outpatient care, with resource use data on frequency of
outpatient care being combined with the relevant unit costs.
Costs for community-based health services and PSS were calculated by applying unit costs extracted from
national tariffs to resource volumes. Costs of medications for individual participants were estimated based
on their reported doses and frequencies, when these were available, or based on an assumed daily dose
using British National Formulary35 recommendations. When a dose range was reported as ‘as required’ or
when the quantities were not recorded, we assumed a mean cost for that medication item based on the
prescription cost analysis values (net ingredient cost per item). If the dose of the medication was missing,
we assumed the patient received the same dosage as other trial participants who reported taking the same
medication.
The costs of equipment that trial participants received to make their daily lives easier and manage
their injury (aids and adaptations) were derived by combining the data on number and type of items
received with their unit cost values. Unit costs were obtained from the NHS supply chain catalogue
(https://my.supplychain.nhs.uk/catalogue; accessed 11 October 2017).
The costs of time taken off work were estimated by applying sex-specific median earnings data from the
annual survey of hours and earnings for part-time and full-time work.36 The employment status of trial
participants was derived from self-reported work status information. Broader societal costs were calculated
by combining the productivity losses and associated loss of earnings as a result of work absences and any
privately incurred costs as a attributable to participants’ surgeries or impaired health states.
Calculation of utilities and quality-adjusted life-years
Participants’ health-related quality of life was assessed using the EQ-5D37 obtained at baseline and at
3, 6 and 12 months post randomisation. The EQ-5D defines health-related quality of life in terms of five
dimensions: (1) mobility, (2) self-care, (3) usual activities, (4) pain/discomfort and (5) anxiety/depression.
Responses in each dimension are divided into three ordinal levels coded: (1) no problems, (2) moderate
problems and (3) extreme problems.
The EQ-5D health states are converted into a single summary index by applying a utility algorithm, which
attaches values (weights) to each permutation of responses to the EQ-5D descriptive system.37 EQ-5D
preference weights have been elicited from general population samples in the UK using the time trade-off
method. The resulting utility scores range from –0.594 to 1.0, with 0 representing death and 1.0 representing
full health; values below 0 indicate health states worse than death. QALYs were calculated as the area under
the baseline-adjusted utility curve and were calculated using linear interpolation between baseline and
follow-up utility scores.
Missing data
Incomplete data are a particular issue in within-trial health economic evaluations and can result from
item-level missingness; for example, when data for visit 2 are missing but data for visit 1 and all visits
after visit 2 are available.38 Consequently, a base-case analysis was constructed when missing data were
imputed using fully conditional multiple imputation made chained equations, under the missing at random
assumption. Multiple imputation under the missing at random assumption provides unbiased estimates of
costs and health consequences. The missing at random assumption was tested through logistic regressions
of missingness of costs and QALYs against baseline covariates.
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Regression models were used to impute unobserved costs and QALYs at each time point and by treatment
allocation using the baseline covariates (age, sex) as predictor variables. Costs and EQ-5D utility scores at
each time point contributed as both predictors and imputed variables. The imputation was run 50 times,
following the rule of thumb that the number of imputations should be similar to the percentage of
incomplete cases.39 The multiple imputation generated 50 data sets using predictive mean matching.
Predictive mean matching provides plausible values when costs and QALYs are non-normally distributed.40
In line with best practice, the MI model was validated by comparing the distributions of the imputed data
with the observed data.40
The multiply imputed data sets were analysed independently with bivariate regressions using a seemingly
unrelated regression model (Sureg) to estimate the costs and QALYs in each treatment group over the
12-month trial horizon. Non-parametric bootstrapping was used to generate joint distributions of costs
and outcomes from the original data set, and changes in costs and QALYs were calculated for each
sample. A total of 1000 bootstrap samples were drawn and means for both incremental costs and
incremental QALYs (with associated 95% CIs) were calculated.
The final step involved combining estimates from each imputed data set using Rubin’s rule to generate an
overall mean estimate of costs and QALYs and the SEs.40 The SE calculated through Rubin’s rules reflects
the variability within and across imputations.
Analyses of resource use, costs and outcome data
Resource use items were summarised by trial allocation group and follow-up period and differences
between groups were analysed using t-tests for continuous variables and Pearson chi-squared (χ2) test for
categorical variables. Means and SEs for values of each cost category were estimated by treatment allocation
and follow-up period. Statistical differences in mean costs by treatment allocation were assessed using
Student t-tests. Mean total costs by treatment allocation and follow-up period were also estimated.
Statistically significant differences in the mean total costs were assessed using non-parametric
bootstrapping, based on 10,000 replications.
We calculated the proportion of patients reporting suboptimal health for each of the five dimensions of
the EQ-5D. Patients were considered to be in suboptimal health if they reported moderate or extreme
problems. We explored whether or not any statistical differences in suboptimal health-related quality of life
existed between the two treatment arms at the different time points, using a Pearson chi-squared (χ2) test.
Cost-effectiveness analyses
Cost-effectiveness results are expressed in terms of the ICER and calculated as the difference between
treatments in mean total costs divided by mean total QALYs. The bootstrap replicates from the non-parametric
bootstrapping, described in Analyses of resource use, costs and outcome data, were used to populate
cost-effectiveness scatterplots. Cost-effectiveness acceptability curves, which showed that the probability that
IM nail fixation is cost-effective relative to locking plate fixation across a range of cost-effectiveness thresholds,
were also generated based on the proportion of bootstrap replicates with positive incremental net benefits.
The net monetary benefit (NMB) of using IM nail fixation versus locking plate fixation was also calculated
across three cost-effectiveness thresholds, namely £15,000 per QALY, £20,000 per QALY and £30,000 per
QALY. A positive incremental NMB indicates that the intervention is cost-effective compared with the
alternative at the given cost-effectiveness threshold.
Sensitivity and subgroup analyses
Several sensitivity analyses were undertaken to assess the impact that uncertain parameters had on
components of the economic evaluation. These involved re-estimating the main cost-effectiveness outcomes
under the following scenarios: (1) restricting the analyses to complete cases (i.e. those with complete cost
and outcome data over the 12-month follow-up period); (2) adopting a wider societal perspective that
included private costs incurred by trial participants and their families, as well as productivity losses and loss
of earnings owing to work absences; (3) estimating the cost-effectiveness under a per-treatment analysis;
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and (4) additionally adjusting the baseline analysis for pre-injury health-related quality of life, which was
assessed using the EQ-5D at baseline.
Subgroup analyses were also conducted for the main cost-effectiveness results to explore heterogeneity in
the trial population. These were conducted by (1) age group (< 50 and ≥ 50 years) and (2) sex (male and
female).
Longer-term economic modelling
The study protocol allowed for decision-analytic modelling to extend the cost-effectiveness of IM nail
fixation, drawing on best-available secondary data sources, supplemented when necessary by expert
opinion.
Results of economic analysis
Table 36, Appendix 4, shows the degree of missing health economic data by treatment allocation and
follow-up time point. The missing data pattern is non-monotonic, as individuals with missing data at one
follow-up time point may return to the trial subsequently. For example, there are more missing EQ-5D data
at 3 months than at 6 months. A similar pattern can be observed for costs.
Health-care resource use
Table 8 summarises the key resource inputs associated with the initial treatment of displaced extra-articular
fractures of the distal tibia. Table 37, Appendix 4, presents details of broader health and social care resource
use over the 12-month follow-up period for complete cases, disaggregated by resource category and period
of follow-up. Generally, resource use at the aggregate level was higher for participants allocated to the locking
plate than those allocated to IM nail fixation, but this was not always statistically significant. The exceptions
were differences in mean total inpatient stay at 6 months (0 vs. 0.11 months), which was statistically significant
at the 5% level (p-value of 0.03), and mean total outpatient care contacts at 6 months (3.64 vs. 4.78 mean
outpatient contacts), which was also significant at the 5% level (p-value of 0.04). The reported number of days
taken off work was generally higher for the locking plate arm. However, the mean difference (46.12 vs. 54.46)
was significant at a 10% significance level at 3 months (p-value of 0.07). Regarding components of the
resource categories, patients in the locking plate arm were more likely to use walking frames at 3 months
(0.20 vs. 0.34), utilise more NHS physiotherapy (1.84 vs. 2.53) at 6 months and report higher use of ‘other’
medicines at 12 months (0.08 vs. 0.29).
Costs
Table 23 summarises the total costs associated with resource use during the trial period among complete
cases by cost category and follow-up period. The mean intervention costs from admission until discharge
were £5585 for IM nail fixation compared with £5615 for locking plate fixation; the mean difference
of £30 was not statistically significant. The mean total NHS and PSS cost throughout the first 6 months
post randomisation was £5876 for IM nail fixation and £6814 for locking plate fixation; the mean cost
difference of £939 was statistically significant at the 5% level. The mean total NHS and PSS cost for the
entire 12-month follow-up period was £6107 for IM nail fixation and £7102 for locking plate fixation; the
mean cost difference of £995 was statistically significant at the 10% significance level. Total societal costs
among cases with complete data are summarised in Table 24. The mean total societal costs throughout
the first 6 months was £9793 for IM nail fixation compared with £12,178 for locking plate fixation; the
mean cost difference of £2385 was statistically significant at the 10% significance level. The mean total
societal costs are £9490 for IM nail fixation and £12,886 for locking plate fixation; the mean cost
difference of £3396 was statistically significant at the 5% significance level.
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TABLE 23 NHS and personal social service costs for cases with complete data by trial allocation, study period and
cost category (£, 2014–15 prices)
Cost category by period
Treatment arm, mean (SE) cost
Mean
difference p-valuea Bootstrap 95% CIbIM nail fixation Locking plate
Baseline to discharge (total, n= 318: IM nail group; n = 158; locking plate group, n= 160)
Intervention costs (includes initial
surgery costs + initial hospital
stay + implants)
5584.86 (107.84) 5615.52 (106.59) –30.66 0.84 –328.02 to 266.70
Discharge to 3 months (total, n= 210: IM nail group, n = 104; locking plate group, n= 106)
Subsequent inpatient care 66.22 (49.31) 229.53 (162.97) –163.31 0.34 –376.63 to 222.79
Outpatient care 137.64 (5.95) 140.71 (7.86) –3.07 0.78 –15.49 to 19.21
Community care 49.01 (9.82) 371.58 (318.06) –322.57 0.31 –764.66 to 242.61
Medications 25.30 (8.36) 32.06 (13.12) –6.76 0.51 –26.01 to 52.51
PSS 0.23 (0.23) 0.85 (0.51) –0.62 0.27 –1.49 to 0.54
Aids and adaptations 8.65 (1.93) 9.02 (1.35) –0.37 0.87 –4.58 to 3.33
Total cost 287.05 (51.42) 783.75 (358.54) –496.70 0.17 –1201.39 to 208.00
Subsequent inpatient care 11.27 (11.20) 121 (63.34) –109.73 0.09 –235.82 to 16.37
Outpatient care 81.43 (7.39) 106.74 (12.98) –25.31 0.09 –54.60 to 3.99
Community care 54.13 (20.35) 154.97 (110.55) –100.84 0.37 –321.55 to 119.87
Medications 8.00 (2.99) 4.28 (1.13) 3.72 0.25 –1.98 to 8.17
PSS 0.56 (0.32) 0.37 (0.26) 0.19 0.361 –0.62 to 1.00
Aids and adaptations 1.40 (0.57) 1.33 (0.49) 0.07 0.92 –1.40 to 1.55
Total cost 156.79 (25.84) 388.70 (128.21) –231.90 0.08 –487.94 to 22.80
6–12 months (total, n= 219: IM nail, n= 108; locking plate group, n= 111)
Subsequent inpatient care 168.00 (66.46) 293.51 (102.88) –125.51 0.31 –331.86 to 147.03
Outpatient care 52.61 (7.79) 58.98 (9.72) –6.37 0.61 –33.08 to 12.48
Community care 15.45 (5.39) 42.37 (28.60) –26.92 0.36 –89.66 to 31.29
Medications 12.53 (9.89) 30.74 (24.58) –18.21 0.49 –48.54 to 23.01
PSS 0.61 (0.44) 0. 64 (0.44) –0.03 0.99 –1.33 to 1.30
Aids and adaptations 0.38 (0.19) 0.35 (0.21) 0.03 0.93 –0.65 to 0.60
Total cost 249.58 (72.38) 426.59 (119.86) –177.01 0.21 –420.89 to 137.92
0–6 months (n= 189 total: IM nail group, n = 91; locking plate group, n= 98)
Initial operation cost 5460.04 (137.92) 5600.11 (137.92) –140.07 0.19 –684.24 to 262.61
Subsequent Inpatient care 40.73 (29.35) 313.14 (187.55) –272.41 0.08 –648.97 to 104.13
Outpatient care 218.66 (11.46) 249.01 (19.49) –30.35 0.09 –75.00 to 14.31
Community care 106.91 (28.42) 601.69 (371.42) –494.78 0.10 –1233.98 to 244.42
Medications 37.73 (10.18) 38.83 (14.28) –1.11 0.47 –35.73 to 33.52
PSS 0.52 (0.52) 0.98 (0.59) –0.46 0.28 –2.02 to 1.10
Aids and adaptations 10.97 (2.30) 10.45 (1.61) 0.52 0.58 –5.02 to 6.06
Total costs throughout first
6 months
5875.56 (124.85) 6814.22 (425.71) –938.66 0.04* –1795.46 to –83.62
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Health outcomes
Table 25 details the number and proportion of individuals reporting each of the EQ-5D dimension levels at
each time point. The proportion of trial participants reporting suboptimal health (moderate to extreme
health outcomes) is also indicated for each dimension and the difference between the two treatment arms
shown by p-values. With the exception of mobility at 3 months [IM nail fixation (81%) vs. locking plate
fixation (89%)], which was statistically significant at the 10% significance level, there were no significant
differences in the proportions of individuals reporting suboptimal health within dimensions between the
two arms at each time point.
TABLE 23 NHS and personal social service costs for cases with complete data by trial allocation, study period and
cost category (£, 2014–15 prices) (continued )
Cost category by period
Treatment arm, mean (SE) cost
Mean
difference p-valuea Bootstrap 95% CIbIM nail fixation Locking plate
0–12 months (total, n = 160: IM nail group, n= 70; locking plate group, n = 78)
Initial operation costs 5428.47 (112.00) 5528.72 (114.25) –100.26 0.53 –671.23 to 298.66
Subsequent inpatient care 234.91 (92.68) 596.25(237.18) –361.34 0.16 –848.35 to 211.12
Outpatient care 268.94 (16.90) 299.14 (26.25) –30.20 0.34 –100.29 to 27.88
Community care 107.09 (23.30) 588.22 (410.64) –481.13 0.25 –1401.81 to 361.51
Medications 58.14 (19.60) 78.45 (35.95) –20.31 0.62 –111.91 to 62.76
PSS 0.32 (0.32) 0.91 (0.64) –0.59 0.40 –2.16 to 0.88
Aids and adaptations 9.45 (2.08) 10.77 (1.89) –1.28 0.65 –7.90 to 2.03
Total costs throughout first
12 months
6107.32 (158.56) 7102.46 (485.18) –995.14 0.05 –2069.63 to –74.93
*Significant difference at the 95% level.
a p-value calculated using the Student’s t-test, two-tail unequal variance.
b Non-parametric bootstrap estimation using 1000 replications.
TABLE 24 Societal costs related to distal fracture fixation for cases with complete data by treatment arm
(£, 2014–15 prices)
Cost category by period
Treatment arm, mean (SE) cost
Mean difference p-valueaIM nail fixation Locking plate
Follow-up period: 0–6 months
NHS and PSS costs 5875.56 (124.85) 6814.22 (425.71) –938.66 0.04
Private costs 16.36 (8.02) 12.46 (3.74) 3.90 0.65
Cost of lost productivity 3901.13 (759.48) 5351.80 (814.56) –1450.67 0.20
Societal costs 9793.05 (761.66) 12,178.48 (1003.33) –2385.43 0.07
Follow-up period: 0–12 months
NHS resource use costs 6107.32 (158.56) 7102.46 (485.18) –995.14 0.06
Private costs 49.52 (35.72) 24.65 (7.80) 24.87 0.48
Cost of lost productivity 3333.28 (649.45) 5758.62 (1032) –2425.34 0.05
Societal costs 9490.12 (658.07) 12,885.73 (1174.33) –3395.61 0.01
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TABLE 25 The EQ-5D descriptive measurements by trial allocation, study period and EQ-5D dimension
Time point
EQ-5D domain level, n (%)
a
Mobility Self-care Anxiety/depression Usual activities Pain/discomfort
Level 1 Level 2 Level 3 Suboptimal Level 1 Level 2 Level 3 Suboptimal Level 1 Level 2 Level 3 Suboptimal Level 1 Level 2 Level 3 Suboptimal Level 1 Level 2 Level 3 Suboptimal
Baseline: IM (n= 157); locking plate (n= 158)
IM nail 3 (2) 44 (28) 110
(70)
154 (98) 19 (12) 109
(69)
29 (18) 138 (88) 64 (41) 74 (47) 18 (11) 92 (59) 5 (3) 28 (18) 124
(79)
152 (97) 6 (4) 92 (59) 59 (38) 151 (96)
Locking
plate
2 (1) 41 (26) 115
(73)
156 (99) 19 (12) 109
(69)
30 (19) 139 (88) 76 (48) 70 (44) 12 (8) 82 (52) 4 (3) 29 (18) 124
(78)
153 (97) 11 (7) 103
(65)
44 (28) 147 (93)
p-value 0.65 0.98 0.94 0.73 0.12
3 months: IM (n= 135); locking plate (n= 141)
IM nail 25 (19) 107
(79)
3 (2) 110 (81) 96 (71) 38 (28) 2 (1) 40 (29) 71 (53) 58
(43)
7 (5) 65 (48) 12 (9) 99 (73) 25 (19) 124 (92) 21 (16) 104
(77)
11 (8) 115 (85)
Locking
plate
15 (11) 125
(89)
1 (1) 126 (89) 92 (65) 49 (35) 0 49 (35) 76 (54) 53
(38)
12 (9) 124 (88) 6 (4) 102
(72)
33 (23) 135 (96) 16 (11) 107
(76)
18 (13) 125 (89)
p-value 0.07 0.34 0.42 0.12 0.31
6 months: IM (n= 142); locking plate (n= 142)
IM nail 64 (45) 77 (54) 1 (1) 78 (55) 116
(82)
26 (18) 0 26 (18) 81 (57) 52
(37)
9 (6) 142 (43) 53 (37) 77 (54) 12 (8) 89 (63) 34 (24) 98 (69) 10 (7) 108 (76)
Locking
plate
57 (40) 85 (60) 0 85 (60) 114
(80)
28 (20) 0 28 (20) 85 (60) 50
(35)
7 (5) 142 (40) 41 (29) 85 (6) 16 (11) 101 (71) 29 (20) 108
(76)
5 (4) 113 (80)
p-value 0.401 0.762 0.72 0.13 0.28
12 months: IM (n= 116); locking plate (n= 118)
IM nail 73 (63) 43 (37) 0 43 (37) 98 (84) 18 (16) 0 18 (16) 77 (66) 35
(30)
3 (3) 38 (33) 61 (53) 51 (44) 4 (3) 55 (47) 37 (32) 73 (63) 6 (5) 79 (68)
Locking
plate
71 (60) 46 (39) 1 (1) 47 (40) 105
(89)
13 (11) 0 13 (11) 82 (69) 31
(26)
5 (4) 36 (31) 68 (58) 43 (36) 7 (6) 50 (42) 41 (35) 72 (61) 5 (4) 77 (65)
p-value 0.66 0.31 0.55 0.44 0.87
a n (%) are the absolute number and percentages of participants in each EQ-5D dimension and ordinal level. Rating of health care was self-reported.
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Cost-effectiveness results
The cost-effectiveness results are presented in Table 26 with locking plate fixation selected as the
comparator. The analytic time horizon covers the entire 12-month follow-up period of the trial. Table 26
shows the joint distribution of incremental costs and outcomes for the base-case analysis, sensitivity
analyses and subgroup analyses. The joint distribution of costs and outcomes for the base-case analysis,
sensitivity analyses and subgroup analyses are graphically represented in Figure 9 using the NMB metric
and in Figure 10 using scatterplots and cost-effectiveness acceptability curves. Plots for the remaining of
the sensitivity analyses that are not shown in Figure 10 mirror the base-case analysis plot. As such, we
elected not to present them.
Base-case analysis
Patients allocated IM nail fixation experienced a non-statistically significant increase in QALYs in the base
case (0.01 QALYs, 95% CI –0.03 to 0.06 QALYs) over a 12-month period. Mean NHS and PSS costs were
significantly lower in the IM nail fixation group (–£970, 95% CI –£1685 to –£256). The ICER for the
base-case analysis indicates that IM nail fixation is the dominant procedure, as average costs for this
intervention were lower and average benefits were greater than those for locking plate fixation.
Assuming cost-effectiveness thresholds of £15,000 per QALY, £20,000 per QALY and £30,000 per QALY,
the probability of cost-effectiveness for IM nail fixation ranged from 0.94 to 0.98 and the NMB associated
with IM nail fixation was positive (see Figure 9). However, the 95% confidence levels for the NMB statistics
overlapped the zero mark; the exception was the NMB at a cost-effectiveness threshold of £15,000 per
QALY, for which the upper and lower limits for the 95% CI were both positive.
Sensitivity analyses
Comparing the mean costs and QALY estimates using different analytical scenarios [complete case, societal
perspective and imputed attributable costs (additionally controlled for pre-injury utility)] supported the
base-case finding (see Table 26, Figures 9 and 10]. However, the per-treatment analysis showed a slightly
different pattern for QALY outcomes (see Table 26 and Figure 10). The results for this analysis indicated
that participants in the IM fixation arm experienced slightly worse health-related quality-of-life outcomes.
However, the result was not statistically significant. The cost difference remained in the same direction as
that for the base-case analysis and indicated that IM fixation was significantly less costly than locking plate
fixation.
Subgroup analyses
The subgroup analyses for age and sex revealed that there was significant interaction between treatment
effect and age group, but this was significant at the 10% significance level (p-value of 0.09); the sex
subgroup analysis did not reveal any statistically significant interactions. IM nail fixation lowered costs for
patients aged < 50 years (–£1468, 95% CI –£3547 to –£291) and moderately increased QALY benefits (see
Table 26). For patients aged ≥ 50 years, IM fixation reduced costs and moderately reduced QALY outcomes,
with an ICER of £60,000 per QALY that fell within the south-west quadrant of the cost-effectiveness plane,
that is, the average costs were less and average benefits were also lower for IM nail fixation than for locking
plate fixation. The 95% CIs for both the costs and QALY estimates suggest considerable uncertainty
surrounding the effects of IM nail fixation for this category of patients; this is graphically depicted in the
NMB forest plot (see Figure 9). Cost-effectiveness acceptability curves for the subgroup analyses show the
differences in probability of cost-effectiveness of IM nail fixation versus locking plate fixation (Figure 11).
According to Figure 11, the probability that IM nail fixation is more cost-effective is higher for individuals
aged < 50 years. There is no observable difference in probability of cost-effectiveness of IM nail fixation
between male and female participants.
Long-term economic modelling
The protocol allowed for long-term decision-analytic modelling of the economic outcomes. We conducted a
further analysis of the health-related quality-of-life outcomes of the trial participants using extended follow-up
data for this trial. This analysis indicated that EQ-5D utility scores for the IM nail fixation and locking plate
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TABLE 26 Cost-effectiveness, cost/QALY (£, 2015): IM nail fixation compared with locking plate fixation
Scenario
Incremental cost
(95% CI)
Incremental QALYs
(95% CI) ICERa
Probability of cost-effectiveness
(willingness-to-pay threshold) NMB (willingness-to-pay threshold)
£15,000 per
QALY
£20,000 per
QALY
£30,000 per
QALY
£15,000 per QALY
(95% CI)
£20,000 per QALY
(95% CI)
£30,000 per QALY
(95% CI)
Base-case analysis
Imputed attributable costs
and QALYs, covariate
adjusted
–970 (–1685 to –256) 0.01 (–0.03 to 0.06) Dominant 0.98 0.97 0.94 1204 (43 to 2465) 1273 (–82 to 2689) 1410 (–385 to 3190)
Sensitivity analyses
Complete-case attributable
costs and QALYs, covariate
adjusted
–1791 (–3986 to –225) 0.04 (–0.02 to 0.09) Dominant 0.99 0.98 0.98 1429 (146 to 2818) 1558 (118 to 3069) 1818 (36 to 3626)
Societal perspective –2230 (–4626 to 167) 0.014 (–0.03 to 0.06) Dominant 0.97 0.97 0.96 2423 (–26 to 5173) 2493 (–93 to 5337) 2626 (–270 to 5706)
Per-treatment analysis –
imputed attributable costs
and QALYs, covariate
adjusted
–875 (–1725 to –26) –0.01 (–0.06 to 0.04) 172,857 (south-west
quadrant)
0.92 0.88 0.81 923 (–347 to 2353) 909 (–570 to 2508) 872 (–1032 to 2861)
Imputed attributable costs
and QALYs, additionally
controlling for pre-injury
utility
–1188 (–2266 to –110) 0.02 (–0.02 to 0.06) Dominant 0.99 0.99 0.98 1518 (212 to 2940) 1633 (180 to 3194) 1862 (66 to 3738)
Subgroup analyses
Base case: aged < 50 years –1468 (–3547 to –291) 0.08 (0 to 0.17) Dominant 0.99 0.98 0.98 1730 (207 to 3320) 1953 (166 to 3804) 2402 (55 to 4830)
Base case: aged ≥ 50 years –821 (–2760 to 1110) –0.022 (–0.09 to 0.05) 60,000 (south-west
quadrant)
0.71 0.67 0.62 709 (–1960 to 3480) 630 (–2320 to 3610) 473 (–3065 to 3930)
Base case: males –1651 (–5042 to –682) 0.05 (–0.07 to 0.17) Dominant 0.71 0.68 0.62 745 (–1945 to 3612) 670 (–2305 to 3741) 520 (–3043 to 4075)
Base case: females –1193 (–5243 to 102) 0.02 (–0.05 to 0.10) Dominant 0.71 0.68 0.62 746 (–1950 to 3643) 673 (–2307 to 3781) 529 (–3049 to 4157)
a Dominance indicates that average costs were less and average benefit greater for IM nail fixation than locking plate fixation.
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– 10,000 – 5000
(a)
5000
Favours IM nail fixation
(incremental NMB > 0)
Favours locking plate fixation
(incremental NMB < 0)
10,0000
Female
Male
Aged ≥ 50 years
Aged < 50 years
Base-case pre-injury utility adjusted
Per-treatment analysis
Societal perspective
Complete case
Base case
– 10,000 – 5000
(b)
5000
Favours IM nail fixation
(incremental NMB > 0)
Favours locking plate fixation
(incremental NMB < 0)
10,0000
Female
Male
Aged ≥ 50 years
Aged < 50 years
Base-case pre-injury utility adjusted
Per-treatment analysis
Societal perspective
Complete case
Base case
– 10,000 – 5000
(c)
5000
Favours IM nail fixation
(incremental NMB > 0)
Favours locking plate fixation
(incremental NMB < 0)
10,0000
Female
Male
Aged ≥ 50 years
Aged < 50 years
Base-case pre-injury utility adjusted
Per-treatment analysis
Societal perspective
Complete case
Base case
FIGURE 9 Forest plots of base-case, sensitivity and subgroup analyses showing the impact on incremental NMB at
cost-effectiveness thresholds of (a) £15,000 per QALY, (b) £20,000 per QALY and (c) £30,000 per QALY.
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FIGURE 10 Cost-effectiveness scatterplots and acceptability curves at 12 months. Base-case analysis (NHS and
personal social service perspective, imputed, intention-to-treat analysis): (a) scatterplot and (b) cost-effectiveness
acceptability curve; complete-case analysis – (c) scatterplot and (d) cost-effectiveness acceptability curve; and
imputed per-treatment analysis – (e) scatterplot and (f) cost-effectiveness acceptability curve. (continued )
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FIGURE 10 Cost-effectiveness scatterplots and acceptability curves at 12 months. Base-case analysis (NHS and
personal social service perspective, imputed, intention-to-treat analysis): (a) scatterplot and (b) cost-effectiveness
acceptability curve; complete-case analysis – (c) scatterplot and (d) cost-effectiveness acceptability curve; and
imputed per-treatment analysis – (e) scatterplot and (f) cost-effectiveness acceptability curve.
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groups were similar at 24 months post randomisation. This analysis was based on sample of 74 (out of 113)
participants who had reached the 24-month follow-up time point at the time of writing. The mean EQ-5D
utility score in the IM nail fixation group was 0.76 (95% CI 0.69 to 0.82) versus 0.80 (95% CI 0.74 to 0.85)
in the locking plate group at 24 months post randomisation. The p-value for the utility score difference of
0.36 was not statistically significant. This indicated that the benefits of IM nail fixation are very likely to be
concentrated in the first year following the treatment of displaced, extra-articular fractures of the distal tibia.
In addition, external studies were systematically searched for comparisons of locking plate and IM nail fixation,
but no good-quality evidence on differences in functional outcomes and health-related quality of life beyond
12 months post surgery could be found. The available studies were based on a short follow-up period,41
had a small sample size,12,42,43 and was a non-randomised study that relied on retrospective reviews or case
series, which tend to suffer from selection bias,11,12,43 or had a combination of these factors. It was, therefore,
concluded that longer-term extrapolation of the cost-effectiveness of IM nail fixation would not be appropriate.
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imputed). (a) Age; and (b) sex.
ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
52
Chapter 5 Summary and discussion
Screening
A large number of patients were screened for eligibility to enter the trial, which is testament to the hard
work of the research teams at each centre. As all patients with a fracture of the tibia are seen by specialist
surgeons on the day that they attend the emergency department and because the great majority of
patients with this fracture are admitted to the hospital, we can be confident that the research teams
screened all potentially eligible patients.
Table 27, Appendix 1, shows the reasons why screened potential patients were not eligible (n = 1581).
The most commonly used exclusion criteria were as expected: the fracture was too proximal (did not extend
within 2 Müller squares of the ankle joint 375/1581, 24%), the fracture was open (369/1581, 23%) or the
fracture extended into the ankle joint (329/1581, 21%). However, the wide variation in totals, by centre,
indicates that some sites screened extensively and recorded any patient with a fracture involving the tibia;
however, others only recorded fractures of the ‘distal’ tibia on the screening logs. Some centres also included
children in their screening log; however, other adult-only trauma centres did not admit any children to their
hospital.
Eligible but did not participate
The reasons why eligible potential participants were not randomised (n = 216) are given in Table 28,
Appendix 1. This information is key to determining the external validity of the trial, that is, the degree to
which the result of the UK FixDT trial can be generalised to the broader population of patients with a
fracture of the distal tibia.
Some of the reasons were inevitable and are unlikely to have created a selection bias within the trial.
The NIHR Clinical Research Network is, generally, unable to provide routine weekend research associate
support for clinical trials, so 53 out of these 216 patients (25%) were not recruited for the reason of ‘no
research staff being available’. Similarly, there were 18 potential participants for whom the reason for
non-participation was on obvious clinical grounds; these reasons included skin around ankle precluded
locking plate fixation (n = 4), primary amputation (n = 3) and hind foot nails used (n = 2). Thirteen patients
(13/216, 6%) declined any surgery, despite this being offered by the clinical team. The number of patients
who declined the trial as they ‘did not want to be part of a research study’ (25/216, 12%) or ‘did not want
to fill in a questionnaire’ (9/216, 4%) was small, which, once again, goes to show that patients with even
severe injuries are keen to take part in research projects.
Patients who were not included in the trial because of a preference for one treatment or the other were
of more potential concern. However, preference for a treatment did not seem to be a important issue
for the patients; only 38 patients (38/216, 18%) expressed a preference, of whom 23 preferred a IM nail
fixation and 15 a locking plate fixation. By contrast, there was a stronger treatment preference among
the surgeons and 57 potentially eligible patients were excluded because the surgeon had a treatment
preference for the patient. Of these 57 participants, 54 were because the surgeon had a preference to use
an IM nail and three were because the surgeon had a preference to use a locking plate. The breakdown of
patients who were potentially eligible but who did not participate by centre is informative. Some centres
had no such patients; however, two centres had 13 (Royal Sussex County Hospital) and eight (Frenchay
Hospital), suggesting that there was a ‘centre’ preference for IM nail fixation in those centres. The Royal
Infirmary of Edinburgh demonstrated this phenomenon very early in their recruitment period and decided
to withdraw from the trial completely after only one patient was recruited.
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Overall, 60% of patients who were potentially eligible to take part in the trial were approached and
agreed to take part. Only 17% of patients who were potentially eligible did not take part in the trial
because of a preference for one treatment or the other; the majority as a result of surgeon preference
rather than a patient preference. Table 3 showed that the baseline characteristics of those patients who
were eligible and recruited versus those who were potentially eligible but not recruited were well matched.
Therefore, in summary, we can be confident that the results of this trial can be extrapolated to the wider
population with a fracture of the distal tibia.
Treatment according to allocation
The CONSORT flow diagram (see Figure 3) shows that 156 out of the 161 patients allocated to IM nail
fixation received the allocated treatment. Of the 160 patients allocated to locking plate fixation, 137 received
the allocated treatment. Therefore, in total, 91% (293/321) of the patients who were randomised received
their allocated treatment.
The fact that fewer patients crossed over from IM nail to locking plate fixation than from locking plate to
IM nail fixation may, again, reflect a surgeon preference for IM nail fixation. However, the number of
crossovers is too small to comment in any meaningful way. Importantly, the small number of crossovers
overall makes it very unlikely that surgeon preference will have affected the result of the trial.
Recruitment by centre
The rate of recruitment by centres varied between < 0.1 pcpm (Basingstoke & North Hampshire Hospital)
and > 1.4 pcpm (University Hospitals of Leicester). To a large degree this was determined by the size of
the catchment area (population served) by the hospital. University Hospitals of Leicester has a very large
catchment compared with Basingstoke & North Hampshire Hospital. Given that some centres were only
open for a few months (Basingstoke & North Hampshire Hospital), and the number of patients presenting
to each centre per month was relatively low, the variation in recruitment rate may also have been affected
by simple variation in presentations over a short period of time.
However, some large-catchment hospitals were open for a relatively long time and still had a low rate of
recruitment, for example Frenchay Hospital and University Hospitals Coventry & Warwickshire. Therefore, it
is more likely that the rate of recruitment in those centres was affected by local recruitment issues. Several
centres reported being affected by staff shortages (King’s College Hospital, Aintree University Hospital).
Only one centre (Royal Infirmary of Edinburgh) withdrew because of lack of equipoise in the local surgeons.
Baseline characteristics of the two groups
Patients
The baseline demographic and clinical characteristics of both treatment groups were well balanced by the
randomisation process (see Table 6). The baseline patient-reported outcome measures also showed good
balance, with similar mean scores being seen across all of the outcomes measures.
Of the 321 patients randomised into the trial, 70% had no preference for which treatment they received.
This is further evidence that the patients did appear to have equipoise having read the participant
information sheet and discussed the trial with the clinical team, as well as with their friends and relatives.
The most common mechanism of injury was a ‘low-energy fall’ and the great majority of patients did not
have any other injuries at the time of their fracture, that is, the majority of distal tibial fractures are isolated
injuries rather than one of multiple injuries in the context of high-energy polytrauma (see Table 6).
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Surgeons
Surgery for fracture of the distal tibia is potentially complicated and may be technically challenging,
depending on the fracture pattern and associated soft-tissue injury. It is, therefore, unsurprising that the
majority of operations in both groups were performed by consultant surgeons: 90 (56%) of IM nail
fixations and 99 (62%) of locking plate fixations. The great majority of the other operations being
performed by a trainee surgeon under supervision by a consultant. As surgery to fix the distal tibia is
technically demanding, surgical assistants are often required. There was, on average, 2.5 surgeons present
in the operating theatre for both the IM nail fixations and locking plate fixations.
Surgery
Full details of the surgery performed are given in Table 8. Of note, the duration of surgery was exactly the
same in both groups of patients, with a mean duration of 2 hours and 4 minutes of operating time. This
contrasts with some previous reports, in which IM nail fixation was found to be a quicker procedure.14
The use of locking plate fixation provides more options for screw fixation distal to the fracture than IM nail
fixation. This is inherent in the design of the implants and, indeed, is one of the theoretical advantages of
locking plate fixation. As expected, the number of screws used in the distal part of the plates was greater
than the number used in the nails. Five or six distal locked screws were used most commonly in the locking
plate fixation group.
The use of blocking (Poller) screws to augment the IM nail fixation of metaphyseal fractures, such as those
in the distal tibia, is the subject of much debate in the orthopaedic trauma community. However, surgeons
in this trial only used blocking screws in 21% of fractures fixed with a tibial nail. The number of cases in
which blocking screws were used is too small to comment on differences between centres and certainly
too small to identify preferences between surgeons.
Intraoperative complications, including extension of the distal tibial fracture into the ankle joint, were rare:
2% in both groups. This is reassuring as one of the often quoted ‘risks’ associated with IM nail fixation is
that the nail may propagate the fracture into the weight-bearing portion of the distal tibial articular surface
at the ankle.
Table 9 shows that the number of patients who crossed over to the other treatment group after
randomisation; this is inevitable in trials of surgical interventions and may be because of intraoperative
clinical reasons or surgeon preference. Of course, there may be some overlap between these reasons,
as an individual surgeon may feel more confident using one technique over another. In technically
demanding surgery, such as fixation of fractures of the distal tibia, this may be a large effect. However,
in the UK FixDT trial, over 91% (293/321) of participants received their allocated treatment. Therefore,
we can be confident that the results of the trial were not unduly affected by crossover of treatment.
Even so, we used the conservative intention-to-treat approach as the primary analysis.
Among those allocated to the IM nail fixation group, 97% (156/161) of participants received their allocated
treatment, and in the locking plate group, 86% (137/160) of participants received their allocated treatment
(there were three participant withdrawals before any intervention was undertaken: two were treated with
external fixation and one was treated with manipulation under anaesthetic only). The small number of
patients who crossed over were spread across all of the centres; the highest being eight patients (University
Hospitals of Leicester), although this centre also had the highest overall recruitment (45 participants). No
other centre had more than three patients crossover treatment, so there did not appear to be a centre-
specific effect. A centre-specific effect in surgical trials may be because of the particular philosophy and/or
training issues in that centre/regional training programme. Again, a preference for one technique may be
more common in technically demanding surgery. The one centre (Royal Infirmary of Edinburgh) that withdrew
from the trial after only one patient was recruited, cited a preference for tibial nail over locking plate and,
therefore, a lack of equipoise. Surgeons at this centre have written a large number of the published literature
on tibial nail fixation, so there may have been an unconscious bias towards this technique.
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Follow-up rate
The sample size for the UK FixDT trial allowed for 20% loss to follow-up. We achieved > 80% follow-up at
each time point. Therefore, we can be very confident that we have achieved sufficient statistical power
according to our prespecified sample size calculation.
Outcomes
Primary outcome
The adjusted estimate of the treatment effect for the DRI score at 3 months, on an intention-to-treat basis,
is 8.8 points (95% CI 4.3 to 13.2 points) in favour of the nail group compared with the locking plate
group. The p-value of < 0.001 indicates that there is strong evidence for a statistically significant difference
in treatment group means at 3 months. The estimated treatment effect was larger than the prespecified
MCID for the DRI score of 8 points. Therefore, at the 3-month time point, the difference between
treatment groups is likely to be clinically important to patients.
However, the adjusted estimate of the treatment effect at 6 months was only 4.0 (95% CI –1.0 to 9.0) in
favour of the IM nail group compared with the locking plate group. Six months was the primary end point
for the trial and is the point upon which the sample size calculation was based. The p-value of 0.114
indicates that there is no evidence for a statistically significant difference in the DRI score between the two
treatment groups at 6 months. The 95% CIs suggest that if there is a difference in the DRI score, it is
unlikely to be clinically important to patients. However, the upper 95% CI does include the prespecified
MCID of 8 points.
At the 12-month time point, the p-value of 0.468 indicates that there is no evidence for a statistically
significant difference in the DRI score between the two treatment groups, the adjusted treatment
difference being 1.9 (95% CI –3.2 to 6.9) in favour of the IM nail fixation group compared with the
locking plate group. At 12 months, the upper 95% CI excludes the MCID.
To complement the preplanned analysis, a post hoc exploratory analysis using DRI score at all four time
points was conducted. This analysis simplified longitudinal data collected at four time points to a single
value, namely the AUC, and facilitated comparisons of the AUCs between treatment groups. Using the
predicted model parameter, the calculated AUC for those allocated to IM nail fixation was 350 units
(SE 16.4 units) and for the locking plate group was 407 units (SE 16.3 units), yielding a between-group
difference of 57 units (95% CI 12 to 103 units). Larger DRI scores represent higher levels of disability, so
larger AUCs are also associated with increased levels of disability. A t-test comparing the values between
groups yielded a p-value of 0.013, indicating there is a statistically significant difference in AUC between
treatment groups. Clinically, this result may be interpreted as evidence that those allocated to locking
plates experienced more disability over the 12-month follow-up period than those allocated to the IM nail
fixation.
In designing the trial, we expected that any difference between these two treatments would most likely
occur around 6 months. However, in the light of uncertainty about the time course of recovery, we also
made assessments at 3 and 12 months. The results show that the largest difference in DRI score actually
occurred at the earlier time point of 3 months. The difference in disability reduced at 6 months, and there
was very little difference at 12 months. In retrospect, we could perhaps have used 3 months as the primary
end point, although traditionally later time points have been used in all trials involving fractures. The very
similar results at 12 months are not too surprising, as the great majority of fractures of the tibia would be
expected to have achieved bony union at this time point; only very large differences in other aspects of
recovery – for instance, muscle strength – would be demonstrated using any outcome measurement tool
at this later time point. However, a minimum of 12-month follow-up is important in such trials so that the
disability associated with delayed or non-union of the fracture can be assessed. Although rare in the
context of this trial, non-union may be more much common in other fractures.
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Overall, the primary outcome result of this trial is good news for patients, in that IM nail fixation is associated
with faster recovery, that is, there is less disability during the early stages of recovery following a fracture of
the distal tibia. This is also an important observation for the design of future trials in fracture healing.
However, it is important for patients to note that, although the DRI scores improve in both groups of patients
over the 12 months following the fracture, they did not return to their pre-injury levels. The average DRI
score at 12 months was still 23 points out of a maximum disability of 100 points.
To set these results into context, we repeated the systematic review of the evidence regarding this question
at the end of the UK FixDT trial. As noted in Chapter 1, Background, there was little evidence in the
literature regarding the pattern of recovery before the trial began. Our updated review found that four trials
have reported since the UK FixDT trial.41,44–47
Vallier et al.44 randomised 104 patients with an extra-articular fracture of the distal tibia to either IM nail fixation
or plate fixation. However, the plates used in this study were ‘non-locking’ plates, that is, traditional ‘large
fragment medial plates’. The authors did not include any patient-reported outcome measures in the initial
report of the trial. They noted a high rate of complications in both arms, including non-union and infection,
which may have affected functional outcome but their results are confounded by the inclusion of patients with
open fractures. The same group subsequently reported later functional outcomes from the participants in their
trial using the Foot Function Index and Musculoskeletal Function Assessment questionnaires.45 They found that
‘scores were not related to plate or nail fixation’ but that both Musculoskeletal Function Assessment and Foot
Function Index scores ‘were worse when knee pain or ankle pain was present’.
Fang et al.46 compared the results of external fixation combined with limited internal fixation with a plate,
minimally invasive percutaneous plate fixation and IM nailing for distal tibia fractures. They concluded that
‘all achieved similar good functional results’. The authors did not report a disability rating, although there
was no evidence of a difference between groups in the American Orthopaedic Foot and Ankle Society
score. However, there were only 28 patients in each group in this trial.
Li et al.41 compared external fixation with both plate and nail fixation. This trial concluded that all three
methods were ‘efficient methods for treating distal tibia fractures’. There was no evidence of difference in
the Mazur ankle score; no disability rating was reported. Again, this study was too small to draw firm
conclusions, with only 137 patients distributed across all three groups.
Polat et al.47 compared IM nail fixation with minimally invasive plate fixation. This trial did not find any
difference in the Foot Function Index, but only 25 patients were included.
Therefore, there is little, if any, evidence with which to compare the main result of the UK FixDT trial.
No other trial reported a disability rating. Other patient-reported scores were used in three trials, each
showing no evidence of a difference between the treatment groups. However, each of these trials was
considerably smaller than the UK FixDT trial and so subject to an increased risk of type II error, that is,
these four trials may not have been large enough to detect a clinically important difference between IM
nail fixation and locking plate fixation, even though one existed.
Secondary outcomes
Patient reported
The secondary patient-reported outcome measures showed the same effect and the same pattern over
time as the DRI score. Each measure showed a large difference in favour of IM nail fixation at 3 months,
which gradually reduced at 6 months and then 12 months after the injury.
This is powerful corroborating evidence that the main result of the UK FixDT trial is real and important to
patients.
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The OMAS is used to assess pain and function of the ankle joint specifically. As the ankle is the closest joint
to the distal tibia, it is likely to be the most affected by both the fracture and the surrounding soft-tissue
injury. The adjusted estimate of the treatment effect for the OMAS, at the 6-month post-randomisation
primary time point, based on an intention-to-treat analysis, was –6.0 points (95% CI –11.2 to –0.7 points)
in favour of the IM nail group compared with the locking plate group. The p-value of 0.026 indicates that
there is evidence for a statistically significant difference in the OMAS between the two treatment groups at
6 months. However, a difference of 6 points on the OMAS scale is unlikely to be particularly important to
patients. Six points on the OMAS scale has been used as an equivalence margin in previous NIHR Health
Technology Assessment trials.25
Similarly, the adjusted estimate of the treatment effect for the EQ-5D index (utility) score, at the 6-month
post-randomisation time point, on an intention-to-treat analysis, was –0.063 (95% CI –0.12 to –0.01)
in favour of the nail group compared with the locking plate group. The p-value of 0.033 indicates that
there is also evidence for a statistically significant difference in the EQ-5D utility score between the two
treatment groups at the 6-month time point.
Weight-bearing status
Data on weight-bearing status were collected at the 6-week follow-up appointment. Only 33% of patients
allocated to the IM nail group reported being fully weight-bearing. However, even fewer (15%) of the
patients in the locking plate group reported being fully weight-bearing.
The p-value for the difference is p < 0.001, indicating strong evidence of a difference between groups. It is
possible that the postoperative instructions given to the two groups of patients were different, although
recent evidence strongly suggests that patients start to bear weight on their leg when they feel comfortable
to do so rather than when the clinical team advise.25
Weight-bearing mobilisation is thought to prevent stiffness in the ankle joint as well as reduced wasting
(loss of strength) in the muscles of the lower leg. It is impossible to know how much of the difference
in disability, ankle function and health-related quality of life noted in the UK FixDT trial at 3 months
resulted from the difference in early weight-bearing status, and we did not record weight-bearing status at
3 months, but it seems likely that the ability to fully bear weight in the IM nail fixation group did at least
contribute to the faster recovery in this group.
Complications
When interpreting the primary outcome of any surgical trial, it is important to take account of the
complication profile of the two procedures. Therefore, we also preplanned a secondary analysis of the
complications occurring in the two groups of patients. We have broken these down into ‘local complications
related to the fracture or its treatment’ and ‘systemic complications potentially related to the fracture or its
treatment’ during the 12 months after the injury.
Local complications related to the fracture or its treatment
In terms of superficial wound healing complications, we expected that there may be more of these in the
locking plate group, as the plate sits on the surface of the distal tibia where there is only a thin soft-tissue
envelope. There were 20 (13%) superficial wound healing complications in the IM nail group and 32 (20%)
in the locking plate group (p = 0.094). Of these superficial wound healing complications,14 (9%) in the IM
nail group and 21 (13%) in the locking plate group were treated with antibiotics in the first 6 weeks after
surgery.
Superficial wound complications are uncomfortable and inconvenient for the patient, but usually resolve in
a few days. Of greater concern are deep surgical site infections, in which the metalwork and, potentially,
the underlying bone are infected. By 12 months, one (1%) of the patients in the IM nail group and five
(3%) in the locking plate group required surgical debridement for deep infection (p = 0.121).
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These findings suggest that, although there were more wound- and infection-related complications in the
locking plate group than the IM nail group, both groups were at risk, including an overall 2% risk of deep
infection.
Other local complications were rare in both groups. There was only one vascular injury, two tendon injuries
and one case of complex regional pain syndrome reported in all 321 patients who took part in the trial.
Deficits in the function of local nerves were reported in the period up to 6 weeks by eight (5%) patients in
the IM nail group and four (3%) in the locking plate group (p = 0.378), but none of these cases required
surgical intervention. We did not specifically ask patients to record symptoms related to nerve injury that
persisted after 6 weeks. However, we expected that any functional deficit or pain related to such a
persistent nerve deficit would affect the patient-reported outcome scores at 3 months and later.
As noted earlier, there have been four trials reported since the UK FixDT trial began.41,45–48 In the most
recent, Fang et al.46 compared the results of external fixation combined with limited internal fixation,
minimally invasive percutaneous plate fixation and IM nailing for distal tibia fractures.46 They concluded
that ‘all achieved similar good functional results’ but that the different surgical techniques may have
different complication profiles. The other trials came to essentially the same conclusion, comparing plate
and nail fixation, although these results may be confounded by the use of non-locking plates in some
cases. Non-locking plates generally require larger incisions and greater soft-tissue ‘stripping’ than ‘locking’
plates, which can be inserted using ‘minimally invasive’ techniques.
External fixation leads to the least soft-tissue stripping of any surgical intervention; the external fixation
pins/wires being inserted through tiny wounds in the skin. This should, in theory at least, lead to lower
rates of infection. However, Fang et al.46 noted that 14% of patients receiving external fixation in their
trial, had ‘pin tract’ infections, that is, infections in the skin around the entry point of the external fixation
pin/wire. This is similar to the number of patients requiring antibiotics for wound complications in the
locking plate group of the UK FixDT trial. Other recent studies have specifically compared external fixation
using ‘fine-wire’ Ilizarov external fixation with plate fixation.48 This trial, although not directly relevant to
the results of the UK FixDT trial, did indicate a lower complication rate with external fixation than with
plate fixation. However, again, the plate fixation group of participants in this trial had an open reduction
and internal fixation with the sort of non-locking plate associated with high wound complication rates.
Therefore, in summary, the most current literature is in keeping with the results of the UK FixDT trial in
terms of complications, that is, the type of complication may differ between interventions but the overall
rate of complications remains high, including in studies using the alternative intervention of external
fixation.
In terms of radiographic malunion, we looked at three parameters to assess ‘deformity’: shortening
(> 10 mm), anteroposterior angulation (> 10°) and lateral angulation (> 5°). We also looked for the
presence or absence of arthritis in the ankle at 12 months.
As one of the theoretical advantages of locking plates is that they provide more options for fixation and,
therefore, more control over the distal segment of the tibia, we expected that there would be more cases of
angular deformity in the IM nail group than the locking plate group. At 6 weeks, there were 12 cases (7%)
of lateral (coronal plane) deformity in the nail group and five (3%) in the locking plate group. There were
five cases of anteroposterior (sagittal plane) deformity in each of the groups. The overall number of angular
deformities was low and there was no statistical evidence of a difference between the groups in terms of
angular deformity. However, at 6 weeks, there were five cases (3%) of shortening of the tibia in the IM nail
group and none in the locking plate group. This difference was statistically significant (p = 0.028) but it is
not clear if this was clinically important to the patients. Overall, as there were very few deformities in either
group, it is difficult to draw any conclusions about the relationship between radiographic deformity and
patient-reported outcome.
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In terms of arthritis in the ankle joint, this was assessed using the radiographs taken at 12 months after
the injury. Ten radiographs (6%) in the IM nail group showed radiological signs of arthritis and 7 (4%) in
the locking plate group, which was not statistically different (p = 0.320). Again, it is not possible to tell if
these cases led to deteriorating function or pain. Longer-term follow-up may answer this question, but
given the low number of cases in either group it is unlikely that long-term review will be able to detect
clinically important differences between treatment groups.
Further surgery related to the distal tibia fracture
Reassuringly, revision of the internal fixation was uncommon in both group: two patients (1%) in the IM
nail group and five patients (3%) in the locking plate group (p = 0.283). Similarly, other (unspecified)
unplanned surgery occurred in only four (2%) and three patients (2%) of the nail and ‘locking’ plate
groups, respectively (p = 1.000).
We anticipated that routine removal of metalwork would be reasonably common in this trial. As any
metalwork inserted in the region of the distal tibia is easily palpable under the patient’s skin, it is more
likely to cause symptoms than in other areas of the body. However, removal of metalwork was required in
only 11 (7%) of the patients in the nail group and 14 (9%) in the ‘locking’ plate group. Of course, these
figures may rise as some patients wait until after 12 months before returning with symptoms related to
their metalwork.
Systematic complications potentially related to the fracture or its treatment
Deep-vein thrombosis occurred in six patients (4%) in the nail group and five patients (3%) in the ‘locking’
plate group (p = 1.000) in the 12 months after the fracture. However, only three deep-vein thromboses
(one in the nail group and two in the locking plate group) occurred in the first 6 weeks following surgery,
when the patients were considered most at risk. It is not possible to know if the later thromboses were
related to the fracture of the distal tibia, but we have included them here for completeness. Of note,
there was only one pulmonary embolus reported in the 321 participants during the 12 months of follow-up.
In terms of systemic but potentially related infections, for example chest, urinary infections, etc., these were
more common; infection treated with antibiotics occurred in 24 patients (15%) of the IM nail group and
31 patients (19%) of the locking plate group (p = 0.303).
Unrelated adverse events
The principal investigator at each centre assessed the ‘relatedness’ of each adverse event. SAEs were
reported by 83 participants, with 23 participants reporting more than one SAE.
Preplanned subgroup and secondary analyses
We preplanned a per-treatment analysis, expecting that some patients allocated to IM nail fixation would
crossover to plate fixation, and vice versa. However, as the number of crossovers was actually small, we did
not expect a difference between the intention-to-treat analysis and the per-treatment analysis. In keeping
with this suggestion, the adjusted per-treatment analysis of the DRI scores at 6 months gave an adjusted
treatment effect of 4.2 points (95% CI –0.9 to 9.2 points; p = 0.103). Adjusted analysis at 3 and 12 months
also gave similar results to the intention-to-treat analysis.
We also preplanned a secondary analysis of the primary outcome measure, taking into account missing
data. As there was very few missing data in the DRI forms at any time point, this analysis did not show any
difference from the complete data analysis.
We also done preplanned subgroup analyses based upon sex and age, using < and ≥ 50 years as a
surrogate for high-energy injuries in younger patients with normal bone density and lower-energy injuries in
older patients with reduced bone density. At the primary outcome time point of 6 months, the p-value of
0.516 indicated there is no evidence for a significant interaction effect between age group and treatment
group. Similarly, the p-value of 0.384 indicates there was no evidence for a significant interaction effect
between sex and treatment group.
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Health economic evaluation
The health economic evaluation is vital to the interpretation of the trial and not only for analysis of the
initial cost of the implants and surgery. As the clinical data presented indicate that patients with a fracture
of the distal tibia have persistent, measurable disability, even 1 year after their fracture, this injury is likely
to have longer-term cost implications for both the health and social care systems.
Cost
The pre-pilot trial that informed the design of the UK FixDT trial suggested that there was considerable cost
related to the choice of implant; at the time the cost of an IM nail and locking bolts was in the region of
£350 and a distal tibia locking plate with screws was around £1200. Interestingly, in addition, operative costs
included the implants used during the surgery, namely nails, plates, locking screws/bolts, blocking screws
and non-locking screws. The estimation of the number of each of these implants used involved prospectively
recording the number of items used for each patient from the operation notes and radiographs. The total
cost of implants for each patient was calculated by combining the resource inputs with their unit cost values;
the latter were derived from NHS trust finance departments.
Table 22 shows that the cost of the nail and four locking bolts had risen a little to approximately £450,
whereas the cost of the medial distal tibial locking plate and eight locking screws had actually fallen to
approximately £650. When the cost of disposable items (guidewire, reaming rod, etc.) is added to the cost
of the IM nail, the difference between the costs of the two types of implant has greatly reduced in the last
few years.
As a consequence, the trial found little difference in the cost of the initial surgical interventions. Neither
was there much difference in the length of the index hospital stay. The total cost of the first admission to
hospital was £5585 in the IM nail group and £5616 in the locking plate group.
However, between discharge from the index hospital stay and 6 months, both the inpatient and the
outpatient health service costs were significantly greater in the locking plate group. The total NHS and
PSS cost to 6 months was £5876 in the nail group and £6814 in the locking plate group, with a mean
difference of £938, which was statistically significant (95% CI £84 to £1795; p = 0.04).
The difference in costs reflects the increased number of investigations, therapy visits and secondary
interventions required in the locking plate group in the early phases of recovery. This fits with the clinical
outcome data presented earlier, in that the number of patients having ‘problems’ was higher in the
locking plate group than the IM nail fixation group. For example, patients with symptoms of wound
infection would have more outpatient appointments, more blood and radiological tests and more in the
way of antibiotic treatment than those without. Another factor contributing to the higher costs in the
locking plate group may have been the higher proportion of patients who were not able to bear weight
on their leg at 6 weeks. It is likely that this explains, at least in part, the increased number of therapy
appointments in the locking plate fixation group.
Between 6 months and 12 months, there are, again, slightly higher costs in the locking plate group,
but the difference between the groups was less than in the earlier phases of recovery. The mean cost
difference to 12 months was £995.14, 95%CI £74.93 to £2069.63; p = 0.05. Further surgery, most
commonly the removal of symptomatic metalwork, is likely to have happened later in the recovery phase
when the surgeon and the patient were confident that the underlying fracture had healed. This may
account for the increased costs in the locking plate group in the later phases of the trial.
A fracture of the distal tibia also has costs for the patient beyond the NHS and PSS perspective. The number
of days off work in the first 3 months after injury was borderline statistically significant in favour of the IM
nail fixation: 46 days in the IM nail group compared with 54 days in the locking plate group (p = 0.07).
Depending upon the patient’s occupation, this may simply be a manifestation of the number of patients
who were weight-bearing at this stage in their recovery, which was higher in the group having IM nail
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fixation. It may also reflect the greater number of days off work required to attend therapy, outpatient and
inpatients visits in the locking plate group, or, most likely, a combination of the two.
Cost-effectiveness
As there is a small QALY gain in the nail group over the 12-month time frame of the trial, and the IM nail
group incurred less cost, the cost-effectiveness evaluation is relatively straightforward to interpret; IM nail
fixation dominates locking plate fixation. Assuming a cost-effectiveness threshold of £20,000 per QALY,
there is a 97% probability that IM nail fixation is cost-effective.
The preplanned sensitivity analyses support this interpretation. The same result was noted with a complete-case
analysis, an analysis including a societal perspective (i.e. including indirect costs, such as those associated with
time off work) and an imputed attributable cost analysis. In the per-treatment analysis, there was a marginal
QALY gain in the locking plate group, so IM nail fixation does not dominate in this scenario. However, the cost
difference remained in the same direction and indicated that IM fixation was generally less costly than locking
plate fixation.
In terms of the preplanned subgroup analyses, sex did not alter the interpretation; IM nail fixation dominates
locking plate fixation in both men and women, that is, on average, it generates QALY gains and lower costs.
The situation was not quite so clear in terms of age. For patients aged < 50 years, IM nail fixation again
dominates, but there is much more uncertainty in patients aged ≥ 50 years. In this subgroup, although the
costs of IM nail fixation were still lower, there were marginally fewer QALY gains, so the ICER was £60,000
per QALY gained in older patients.
Overall, the health economic evaluation provides strong evidence that IM nail fixation incurs less cost
than locking plate fixation and marginally greater QALY gains. So, at any level of the cost-effectiveness
threshold, IM nail fixation can be considered cost-effective.
Limitations
There are, of course, some limitations to the trial. Two hundred and sixteen potentially eligible participants
were not randomised, which could pose a risk to the external validity (generalisability) of the trial. However,
most of these patients were excluded for logistical reasons (e.g. no research staff available at the weekend),
for good clinical reasons (e.g. declined any surgery) or because the patient ‘did not want to be’ part of a
research study or fill out questionnaires’. There is no reason to suspect that these patients created a
selection bias within the trial.
Patients who had a preference for one treatment or the other were of more concern. However, preference
of treatment did not seem to be common among the patients; only 38 patients expressed a preference,
of whom 23 preferred a IM nail and 15 a locking plate fixation. However, there was a stronger treatment
preference among the surgeons, by whom 57 potentially eligible patients were excluded; 54 of these
patients were excluded because the surgeon had a preference to use an IM nail. This does suggest that
there was a preconceived preference for IM nail fixation, at least among surgeons in some centres.
However, if patients deemed ‘suitable only for a nail’ were excluded, despite being eligible according to
the trial criteria, this is only likely to have reduced the relative benefit of IM nail fixation compared with
locking plate fixation. Despite this possible effect, the trial still showed an overall benefit of IM nail fixation.
Other possible limitations included post-randomisation crossover of patients from one group to the other.
However, there were fewer than expected. Ninety-one per cent of patients received the treatment to
which they had been allocated.
Similarly, some loss to follow-up was expected. However, the sample size was inflated to account for loss to
follow-up of ≥ 20%, and < 20% of participants were lost from the primary outcome analysis at every time point.
Finally, as wound dressings after surgery are clearly visible, it was not possible to blind the patients to their
treatment allocation.
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Chapter 6 Conclusion
Among adults with an acute fracture of the distal tibia who were randomised to IM nail fixation orlocking plate fixation, there were similar disability ratings at 6 months. However, recovery across all
outcomes was faster in the IM nail fixation group and costs were lower.
Future work should address the potential clinical effectiveness and cost-effectiveness benefit of IM nail
fixation in other metaphyseal fractures, such as the distal and proximal femur. Research is also required
into the role of adjuvant treatment and different mobilisation strategies to accelerate recovery in tibial
fractures treated with IM nail fixation. The patients in this trial will remain in longer-term follow-up.
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TABLE 27 Reasons screened patients were not eligible for the study, by site
Reason
Site (n)
University
Hospitals
Coventry &
Warwickshire
Addenbrookes
Hospital
Frenchay
Hospital
University
Hospitals
of
Leicester
Nottingham
University
Hospitals
James
Cook
Hospital
Aged < 16 years 13 0 36 5 0 19
Fracture does not extend
within 2 Müller squares
28 23 76 27 7 35
Surgeon thinks patient
would not benefit
0 0 0 1 0 0
Surgeon believes no
operation preferable
6 0 22 6 4 0
Surgeon believes external
fixation preferable
5 1 0 1 2 4
Surgeon believes
contraindication to nail
0 0 1 0 0 0
Fracture too low for distal
locking screws
8 1 11 4 0 5
Obstruction to IM nail 4 0 3 1 0 2
Fracture is open 21 16 84 8 4 22
Patient contraindication to
anaesthesia
1 0 6 2 1 0
Patient has permanent
cognitive impairment
4 9 11 0 3 5
Fracture extends in to the
ankle joint
5 7 39 4 6 25
Total 95 57 289 59 27 117
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John
Radcliffe
Hospital
Aberdeen
Royal
Infirmary
Derriford
Hospital
Royal
Stoke
University
Hospital
Royal
Sussex
County
Hospital
Royal
Victoria
Infirmary
Glasgow
Royal
Infirmary
Royal
Berkshire
Hospital
Poole
Hospital
23 0 0 0 0 0 2 4 9
26 2 4 21 19 5 3 7 15
0 0 0 0 0 0 0 0 1
12 7 2 1 2 7 1 3 12
4 0 0 4 1 0 0 2 3
1 0 0 0 0 0 0 0 0
1 3 1 1 1 2 3 0 6
1 2 2 0 0 1 0 0 1
61 18 0 4 22 22 19 0 7
2 2 0 0 0 0 0 2 0
7 9 1 5 1 3 12 1 1
19 23 5 9 37 14 18 2 17
157 66 15 45 83 54 58 21 72
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Reason
Site (n)
Queen
Alexandra
Hospital
King’s
College
Hospital
Aintree
University
Hospital
Southampton
General
Hospital
University
Hospitals of
Birmingham
Aged < 16 years 10 0 0 0 0
Fracture does not extend
within 2 Müller squares
11 1 13 14 25
Surgeon thinks patient
would not benefit
0 0 0 0 0
Surgeon believes no
operation preferable
0 0 1 0 7
Surgeon believes external
fixation preferable
0 0 0 2 2
Surgeon believes
contraindication to nail
1 0 0 0 1
Fracture too low for distal
locking screws
3 0 3 0 5
Obstruction to IM nail 0 0 0 0 5
Fracture is open 2 0 0 6 4
Patient contraindication to
anaesthesia
0 0 0 0 0
Patient has permanent
cognitive impairment
2 1 1 2 2
Fracture extends in to the
ankle joint
7 3 4 1 22
Total 36 5 22 25 73
TABLE 27 Reasons screened patients were not eligible for the study, by site (continued)
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Total,
n (%)
Leeds Teaching
Hospital
St George’s
Hospital
Hull Royal
Infirmary
North
Tyneside
General
Hospital &
Wansbeck
General
Heartlands
Hospital
Sunderland
Royal
Hospital
7 1 0 3 2 0 134 (8)
8 0 2 3 0 0 375 (24)
0 0 0 0 0 0 2 (< 1)
6 0 3 3 3 0 108 (7)
23 0 5 1 1 2 63 (4)
0 0 0 0 0 0 4 (< 1)
4 0 0 3 0 0 65 (4)
2 2 0 1 0 0 27 (2)
6 41 0 2 0 0 369 (23)
0 0 0 0 0 0 16 (1)
5 0 0 3 0 1 89 (6)
33 4 12 12 1 0 329 (21)
94 48 22 31 7 3 1581
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TABLE 28 Reasons potentially eligible patients were not recruited to the study, by site
Reason
Site (n)
University
Hospitals
Coventry &
Warwickshire
Addenbrookes
Hospital
Frenchay
Hospital
University
Hospitals
of
Leicester
Nottingham
University
Hospitals
James
Cook
Hospital
Patient wants nail 3 1 1 1 3 0
Patient wants plate 0 0 1 2 0 1
Patient does not want
surgery
1 0 1 0 0 0
Patient does not want to
be part of research study
3 2 1 1 0 0
Patient does not want to
complete questionnaires
1 0 1 0 0 3
Research staff unavailable 1 2 13 2 0 2
Surgeon preferred nail 0 5 8 0 3 1
Surgeon preferred plate 0 0 1 1 0 0
Other 1 0 2 1 0 0
No reason given 0 0 0 0 0 1
Total 10 10 29 8 6 8
John
Radcliffe
Hospital
Aberdeen
Royal
Infirmary
Derriford
Hospital
Royal
Stoke
University
Hospital
Royal
Sussex
County
Hospital
Royal
Victoria
Infirmary
Glasgow
Royal
Infirmary
Royal
Berkshire
Hospital
Poole
Hospital
1 4 0 0 0 0 3 0 1
1 0 0 0 0 0 0 1 6
0 1 0 0 0 0 1 0 1
0 5 0 2 0 0 3 3 0
0 2 0 1 0 0 0 0 0
3 0 0 1 4 3 4 1 5
2 5 3 1 13 0 3 3 0
0 0 0 1 0 0 0 0 0
1 0 0 3 0 2 0 0 4
0 0 0 0 0 2 0 0 0
8 17 3 12 17 7 14 8 17
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TABLE 28 Reasons potentially eligible patients were not recruited to the study, by site (continued)
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Reason
Site (n)
Queen
Alexandra
Hospital
King’s
College
Hospital
Aintree
University
Hospital
Southampton
General
Hospital
University
Hospitals of
Birmingham
Patient wants nail 2 0 0 0 0
Patient wants plate 1 0 0 0 1
Patient does not want
surgery
0 0 0 0 1
Patient does not want to
be part of research study
0 0 0 0 1
Patient does not want to
complete questionnaires
1 0 0 0 0
Research staff unavailable 2 0 1 4 3
Surgeon preferred nail 0 0 0 2 0
Surgeon preferred plate 0 0 0 0 0
Other 1 0 0 2 0
No reason given 0 0 0 0 0
Total 10 0 1 9 6
Total,
n (%)
Leeds
Teaching
Hospital
St George’s
Hospital
Hull Royal
Infirmary
North
Tyneside
General
Hospital &
Wansbeck
General
Heartlands
Hospital
Sunderland
Royal
Hospital
3 0 0 0 0 0 23 (11)
1 0 0 0 0 0 15 (7)
5 0 2 0 0 0 13 (6)
3 0 1 0 0 0 25 (12)
0 0 0 0 0 0 9 (4)
1 0 0 1 0 0 53 (25)
2 0 3 0 0 0 54 (25)
0 0 0 0 0 0 3 (1)
1 0 0 0 0 0 18 (8)
0 0 0 0 0 0 3 (1)
16 0 6 1 0 0 216
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TABLE 29 Recruitment by site and month
Site Date open
Year (n)
Total
(n)
Months
(n)
Rate
(n)2013 2014
2015 2016
January February March April May June July August September October November December January February March April
University Hospitals
Coventry &
Warwickshire
8 April 2013 9 14 0 0 0 1 2 4 2 0 1 2 0 1 0 1 1 0 38 36 1.06
Addenbrookes Hospital 2 May 2013 2 7 3 0 1 0 1 0 0 1 0 0 0 0 0 0 0 0 15 35 0.43
Frenchay Hospital 12 June 2013 3 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 8 34 0.24
University Hospitals of
Leicester
16 July 2013 6 19 2 1 1 0 2 2 1 3 1 0 2 1 1 1 1 1 45 32 1.41
Nottingham University
Hospitals
25 July 2013 4 5 1 1 0 1 1 0 0 0 1 0 0 0 1 0 0 0 15 32 0.47
James Cook Hospital 5 September 2013 1 6 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 9 31 0.29
John Radcliffe Hospital 20 December 2013 0 3 0 0 0 0 0 2 1 0 1 0 1 0 3 3 0 1 15 28 0.54
Aberdeen Royal
Infirmary
14 January 2014 8 2 2 1 0 0 0 0 1 0 0 1 1 0 0 0 1 17 27 0.63
Derriford Hospital 15 January 2014 8 0 1 0 1 1 2 0 0 0 0 0 0 0 0 0 0 13 27 0.48
Royal Stoke University
Hospital
31 January 2014 3 1 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 6 27 0.22
Royal Sussex County
Hospital
3 February 2014 5 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 7 26 0.27
Royal Infirmary of
Edinburgh
10 February 2014 1 1 10 0.10
Royal Victoria Infirmary 10 February 2014 8 1 0 0 1 2 1 1 0 1 1 2 0 0 0 0 0 18 26 0.69
Glasgow Royal
Infirmary
11 March 2014 7 0 1 1 1 0 0 0 5 1 0 2 0 1 0 1 0 20 26 0.77
Royal Berkshire
Hospital
8 May 2014 1 0 0 0 0 0 1 0 1 1 1 1 0 0 0 0 0 6 24 0.25
Poole Hospital 13 May 2014 2 0 1 0 1 0 0 0 2 0 1 0 2 0 0 0 0 9 24 0.38
Queen Alexandra
Hospital
29 May 2014 2 1 0 1 2 1 1 0 1 3 0 0 1 0 0 0 0 13 24 0.54
King’s College Hospital 10 June 2014 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 2 23 0.09
Aintree University
Hospital
15 July 2014 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 22 0.09
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Site Date open
Year (n)
Total
(n)
Months
(n)
Rate
(n)2013 2014
2015 2016
January February March April May June July August September October November December January February March April
Southampton General
Hospital
4 August 2014 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 2 21 0.10
University Hospitals of
Birmingham
6 August 2014 1 1 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 5 21 0.24
Leeds Teaching
Hospital
12 August 2014 2 3 1 2 0 3 2 1 0 1 1 1 2 2 0 0 0 21 21 1.00
St George’s Hospital 10 September 2014 2 1 0 0 0 1 0 0 1 1 0 0 0 0 0 0 0 6 20 0.30
Hull Royal Infirmary 13 October 2014 0 0 0 3 1 2 0 0 0 0 1 0 0 0 0 1 0 8 19 0.42
North Tyneside General
Hospital & Wansbeck
General
20 November 2014 2 0 1 1 0 0 1 1 0 1 0 0 0 0 1 1 2 11 18 0.61
Heartlands Hospital 3 February 2015 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 15 0.13
Sunderland Royal
Hospital
4 March 2015 2 1 1 0 1 0 0 0 1 0 0 0 0 0 6 14 0.43
Basingstoke & North
Hampshire Hospital
1 April 2015 0 0 0 0 0 0 0 0 1 0 0 0 0 1 13 0.08
Total 25 114 16 12 15 11 17 17 8 17 16 8 11 10 8 6 5 5 321 676 0.47
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TABLE 30 Randomised patients summarised by treatment group and centre
Site
Treatment group (n)
TotalIM nail fixation Locking plate
Aberdeen Royal Infirmary 9 8 17
Addenbrookes Hospital 7 8 15
Aintree University Hospital 1 1 2
Heartlands Hospital 1 1 2
Basingstoke & North Hampshire Hospital 1 0 1
Royal Infirmary of Edinburgh 1 0 1
Frenchay Hospital 4 4 8
Glasgow Royal Infirmary 10 10 20
Hull Royal Infirmary 5 5 10
James Cook Hospital 5 4 9
John Radcliffe Hospital 7 8 15
King’s College Hospital 1 1 2
Leeds Teaching Hospital 10 11 21
North Tyneside General Hospital & Wansbeck General 5 4 9
Nottingham University Hospitals 8 7 15
Derriford Hospital 6 7 13
Poole Hospital 4 5 9
Queen Alexandra Hospital 7 6 13
Royal Berkshire Hospital 3 3 6
Royal Sussex County Hospital 3 4 7
Royal Victoria Infirmary 8 10 18
St George’s Hospital 3 3 6
Sunderland Royal Hospital 3 3 6
University Hospitals of Birmingham 3 2 5
University Hospitals Coventry & Warwickshire 19 19 38
University Hospitals of Leicester 23 22 45
Southampton General Hospital 1 1 2
Royal Stoke University Hospital 3 3 6
Total 161 160 321
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TABLE 31 Randomised patients summarised by randomisation strata (recruiting site and age group)
Site
Age (years) group (n)
< 50 ≥ 50
IM nail
fixation
Locking
plate
IM nail
fixation
Locking
plate
Aberdeen Royal Infirmary 7 6 2 2
Addenbrookes Hospital 4 4 3 4
Aintree University Hospital 1 0 0 1
Heartlands Hospital 0 1 1 0
Basingstoke & North Hampshire Hospital 0 0 1 0
Royal Infirmary of Edinburgh 0 0 1 0
Frenchay Hospital 2 2 2 2
Glasgow Royal Infirmary 5 4 5 6
Hull Royal Infirmary 2 4 3 1
James Cook Hospital 3 3 2 1
John Radcliffe Hospital 5 6 2 2
King’s College Hospital 1 1 0 0
Leeds Teaching Hospital 3 6 7 5
North Tyneside General Hospital & Wansbeck
General
3 4 2 0
Nottingham University Hospitals 6 5 2 2
Derriford Hospital 3 5 3 2
Poole Hospital 4 2 0 3
Queen Alexandra Hospital 5 2 2 4
Royal Berkshire Hospital 3 1 0 2
Royal Sussex County Hospital 3 3 0 1
Royal Victoria Infirmary 8 7 0 3
St George’s Hospital 2 2 1 1
Sunderland Royal Hospital 3 2 0 1
University Hospitals of Birmingham 1 1 2 1
University Hospitals Coventry & Warwickshire 11 12 8 7
University Hospitals of Leicester 11 11 12 11
Southampton General Hospital 1 0 0 1
Royal Stoke University Hospital 0 3 3 0
Total 97 97 64 63
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Appendix 2 Details of missing data
TABLE 32 Summary of missing responses to DRI questionnaire items
DRI item
Time point (n)
Baseline 3 months 6 months 12 months
IM nail
fixation
(n= 160)
Locking
plate
fixation
(n= 158)
IM nail
fixation
(n= 134)
Locking
plate
fixation
(n= 142)
IM nail
fixation
(n= 143)
Locking
plate
fixation
(n= 141)
IM nail
fixation
(n= 128)
Locking
plate
fixation
(n= 130)
Dressing 0 0 0 0 0 0 0 0
Outdoor walks 0 0 0 0 0 0 0 0
Climbing stairs 0 0 0 0 1 0 0 0
Sitting longer time 0 0 1 0 0 0 0 1
Standing bent over a sink 0 0 0 1 0 0 0 0
Carrying a bag 0 0 0 0 0 0 0 0
Making a bed 0 0 0 0 0 0 0 0
Running 0 0 0 0 0 0 1 0
Light work 0 0 0 0 0 0 1 0
Heavy work 0 1 0 0 0 1 1 0
Lifting heavy objects 0 0 0 0 0 0 0 0
Participating in exercise or
sports
0 0 1 0 0 0 1 0
TABLE 33 Summary of missing responses to OMAS questionnaire items
OMAS item
Time point (n)
Baseline 3 months 6 months 12 months
IM nail
fixation
(n= 159)
Locking
plate
fixation
(n= 158)
IM nail
fixation
(n= 134)
Locking
plate
fixation
(n= 142)
IM nail
fixation
(n= 140)
Locking
plate
fixation
(n= 140)
IM nail
fixation
(n= 123)
Locking
plate
fixation
(n= 130)
Pain 0 0 1 1 0 0 0 0
Stiffness 0 0 1 0 0 1 0 0
Swelling 0 0 1 0 0 1 0 0
Stairs 0 0 0 0 0 0 0 0
Running 0 0 0 0 1 0 0 1
Jumping 0 0 0 0 0 2 0 0
Squatting 2 0 1 0 0 0 1 0
Supports 0 1 1 2 0 1 2 0
Daily life 0 0 0 1 0 0 0 0
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TABLE 34 Summary of missing responses to EQ-5D questionnaire items
EQ-5D domain
Time point (n)
Baseline pre injury Baseline post injury 3 months 6 months 12 months
IM nail
fixation
(n= 160)
Locking plate
fixation
(n= 158)
IM nail
fixation
(n= 158)
Locking plate
fixation
(n= 158)
IM nail
fixation
(n= 134)
Locking plate
fixation
(n= 143)
IM nail
fixation
(n= 143)
Locking plate
fixation
(n= 140)
IM nail
fixation
(n= 129)
Locking plate
fixation
(n= 130)
Mobility 0 0 0 0 0 1 0 0 0 0
Self care 0 0 0 0 0 0 0 0 0 0
Usual activities 0 0 0 1 0 0 0 0 0 0
Pain and discomfort 0 0 0 0 0 0 0 0 0 0
Anxiety and depression 0 1 0 1 0 0 0 0 1 0
VAS 1 0 0 1 0 1 0 0 1 1
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Appendix 3 Example follow-up questionnaire
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The EQ-5D-3L has been reproduced with permission.
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leHealth Questionnaire
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Appendix 4 Economic supplementary data
TABLE 35 Summary of unit cost data and data sources
Resource item
Unit
cost (£) Unit of analysis Source of unit cost
Subsequent inpatient care
Orthopaedics (your leg)
Cost per average LoS
of 1 day
1780.34 Per procedure Reference Costs 2014–15; ‘minor knee procedures
for non-trauma, 19 years and over’ – HN25A33
Day case 1349.10 Per procedure Reference Costs 2014–15; ‘minor knee procedures
for non-trauma, 19 years and over’ – HN25A33
Orthopaedics (any other bones)
Cost per average LoS
of 4 days
2648.56 Per procedure Reference Costs 2014–15; ‘other muscle, tendon,
fascia or ligament procedures’ – HN93Z33
Day case 965.19 Per procedure Reference Costs 2014–15; ‘other muscle, tendon,
fascia or ligament procedures’ – HN93Z33
Adjustment per
day ± average LoS
(excess bed-days)
278.52 Per day Reference Costs 2014–15; ‘other muscle, tendon,
fascia or ligament procedures’ – HN93Z33
Other inpatient
Rehabilitation unit 335.00 Per session Reference Costs 2013–14; ‘rehabilitation for other
trauma’ – V636Z49
Outpatient care
Orthopaedics 112.50 Per session Reference Costs 2014–1533
Blood tests/phlebotomy 3.00 Per test Reference Costs 2014–1533
Radiology
Radiography 30.23 Per test Reference Costs 2014–1533
Magnetic resonance
imaging
146.00 Per test Reference Costs 2014–1533
Computerised
tomography
111.00 Per test Reference Costs 2014–1533
Hospital physiotherapist
(NHS)
38.00 Per session Unit Costs of Health and Social Care 2015, p. 217 34
Physiotherapist (private) 70.00 Per hour The Physio Centre (URL: www.thephysiocentre.co.uk/
how_much/; accessed 3 October 2017)
Emergency department
Orthopaedics and
trauma
112.50 Per session Reference Costs 2014–1533
Other 140.59 Per session Reference Costs 2014–1533
Primary and community care
GP
Surgery consultation 225.00 Per hour Unit Costs of Health and Social Care 2015, p. 17834
Home visit 5.20 Per home visit minute Unit Costs of Health and Social Care 2010, p. 16750
Telephone call 27.00 Per telephone
consultation lasting
7.1 minutes
Unit Costs of Health and Social Care 2015, p. 17834
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TABLE 35 Summary of unit cost data and data sources (continued )
Resource item
Unit
cost (£) Unit of analysis Source of unit cost
Practice nurse 56.00 Per hour of face-to-face
contact
Unit Costs of Health and Social Care 2015, p. 17434
District nurse 67.00 Per hour of patient
related work
Unit Costs of Health and Social Care 2015, p. 16934
Community
physiotherapist
36.00 Per hour of consultation Unit Costs of Health and Social Care 2015, p. 17934
Occupational therapist 44.00 Per hour Unit Costs of Health and Social Care 2015, p. 19134
PSS
Meals on Wheels
Frozen, daily 46.00 Per weekly meal Unit Costs of Health and Social Care 2014, p. 12751
Hot, daily 44.00 Per weekly meal Unit Costs of Health and Social Care 2014, p. 12751
Laundry services 4.55 Per load North Yorkshire Country Council (URL: www.
northyorks.gov.uk/article/23988/Paying-for-social-
care-services-in-the-community; accessed 3 October
2017)
Social worker contacts 42.00 Per hour Unit Costs of Health and Social Care 2015, p. 9534
Care worker contacts
including help at home
24.00 Per hour Unit Costs of Health and Social Care 2015, p. 19234
Aids and adaptations
Crutches 5.06 Per unit NHS Supply Chain 2016 (URL: https://my.
supplychain.nhs.uk/catalogue; accessed 3 October
2017)
Stick 3.94 Per unit NHS Supply Chain 2016 (URL: https://my.supplychain.
nhs.uk/catalogue; accessed 18 July 2016)
Walking frame 35.99 Per unit NHS Supply Chain 2016 (URL: https://my.supplychain.
nhs.uk/catalogue; accessed 18 July 2016)
Grab rail 1.61 Per unit NHS Supply Chain 2016 (URL: https://my.supplychain.
nhs.uk/catalogue; accessed 18 July 2016)
Dressing aids 1.66 Per unit NHS Supply Chain 2016 (URL: https://my.supplychain.
nhs.uk/catalogue; accessed 18 July 2016)
Long-handle shoe horn 1.66 Per unit NHS Supply Chain 2016 (URL: https://my.supplychain.
nhs.uk/catalogue; accessed 18 July 2016)
Productivity losses
Median wage rate
Full time, male 567.00 Per week Annual Survey of Hours and Earnings: 201536
Full time, female 471.00 Per week Annual Survey of Hours and Earnings: 201536
Part time, male 156.00 Per week Annual Survey of Hours and Earnings: 201536
Part time, female 171.00 Per week Annual Survey of Hours and Earnings: 201536
Median earnings
(self-employed)
10,800.00 Per year The Income of the Self-Employed52
GP, general practitioner; LoS, length of stay.
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TABLE 36 Number and proportion of individuals with missing health economic data by treatment allocation
Variable Description
Treatment group, missing values, n (%)
IM nail fixation
(n= 158)
Locking plate
(n= 160) Total
eq5db EQ-5D index score pre injury 1 (1) 1 (1) 2 (1)
eq5d0 EQ-5D index score post injury 2 (1) 3 (2) 5 (2)
eq5d1 EQ-5D at 3 months 23 (15) 19 (12) 42 (13)
eq5d2 EQ-5D at 6 months 16 (10) 18 (11) 34 (11)
eq5d3 EQ-5D at 12 months 43 (27) 42 (26) 85 (27)
c0 Operative costs (surgery cost including initial hospital
stay and implants)
0 (0) 0 (0) 0 (0)
c1 Total resource use between baseline and 3 months 54 (34) 54 (34) 108 (34)
c2 Total resource use between 3 and 6 months 30 (19) 31 (19) 61 (19)
c3 Total resource use between 6 and 12 months 60 (38) 58 (36) 118 (37)
c4 Total resource use between 0 and 6 months 67 (42) 62 (39) 129 (41)
c5 Total resource use between 0 and 12 months 88 (56) 82 (51) 170 (54)
TABLE 37 Use of health-care resources related to distal fracture fixation by each follow-up period and treatment
arm (complete cases)
Health-care resource
Treatment group
Difference:
p-value of t-testIM nail fixation Locking plate
Six-week follow-up
Inpatient care, mean length of stay in days (SE)
Intensive care 0.11 (0.06) 0.41 (0.39) 0.45
Acute trauma 5.78 (0.36) 5.83 (0.35) 0.92
Rehabilitation 0.55 (0.30) 0.19 (0.09) 0.26
Other 0.17 (0.07) 0.21 (0.12) 0.78
Total inpatient care use 6.61 (0.47) 6.64 (0.39) 0.62
Proportion of participants prescribed antibiotics at 6 weeks (SD) 0.14 (0.35) 0.13 (0.03) 0.69
Three-month follow-up
Subsequent inpatient care, mean length of stay in days (SE)
Orthopaedics
Leg 0.09 (0.05) 0.18 (0.12) 0.25
Other bones 0 0
Rehabilitation unit 0 0.09 (0.09) 0.16
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TABLE 37 Use of health-care resources related to distal fracture fixation by each follow-up period and treatment
arm (complete cases) (continued )
Health-care resource
Treatment group
Difference:
p-value of t-testIM nail fixation Locking plate
Other
Surgery 0.03 (0.03) 0.11 (0.11) 0.24
Non-surgery 0 0.01 (0.01) 0.16
Total inpatient care use 0.12 (0.06) 0.38 (0.24) 0.16
Outpatient care, mean number of contacts (SE)
Orthopaedics 1.66 (0.12) 1.93 (0.15) 0.09
Pathology 0.07 (0.03) 0.08 (0.03) 0.85
Radiology
Radiography 1.26 (0.21) 1.38 (0.11) 0.21
Magnetic resonance imaging 0.01 (0.01) 0.03 (0.01) 0.09
Computerised tomography 0 0.03 (0.01) 0.02
Physiotherapy
NHS 1.82 (0.21) 1.69 (0.19) 0.67
Private 3.59 (3.26) 0.16 (0.10) 0.86
Emergency department
Fracture related 0.10 (0.03) 0.08 (0.03) 0.66
Other reasons 0.02 (0.01) 0.03 (0.02) 0.25
Other 0.06 (0.02) 0.08 (0.03) 0.30
Total outpatient care use 8.59 (3.25) 5.50 (0.33) 0.83
Community health care, mean number of contacts (SE)
GP contacts
Surgery consultation 0.92 (0.13) 0.97 (0.16) 0.39
Home visit 0.14 (0.06) 0.11 (0.05) 0.62
Telephone call 0.36 (0.10) 0.46 (0.10) 0.24
Practice nurse contacts 0.64 (0.19) 0.39 (0.10) 0.88
District nurse contacts 2.61 (0.92) 1.13 (0.49) 0.92
Community physiotherapy contacts 0.59 (0.15) 0.71 (0.18) 0.31
Occupational therapy contacts 0.29 (0.13) 0.26 (0.11) 0.56
Other 0.10 (0.10) 0.22 (0.17) 0.27
Total community health-care use 5.64 (0.97) 4.25 (0.56) 0.89
Aids and adaptations, mean count (SE)
Crutches 1.05 (0.09) 1.21 (0.10) 0.11
Stick 0.12 (0.03) 0.06 (0.03) 0.91
Walking frame 0.20 (0.04) 0.34 (0.06) 0.03*
Grab rail 0.12 (0.04) 0.09 (0.04) 0.70
Dressing aids 0.33 (0.24) 0.11 (0.08) 0.80
Long-handle shoe horn 0.03 (0.02) 0.01 (0.01) 0.81
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TABLE 37 Use of health-care resources related to distal fracture fixation by each follow-up period and treatment
arm (complete cases) (continued )
Health-care resource
Treatment group
Difference:
p-value of t-testIM nail fixation Locking plate
Other 0.70 (0.10) 0.68 (0.10) 0.57
Total use – aids and adaptations 2.55 (0.30) 2.51 (0.18) 0.65
Medicines, proportion of participants prescribed each class of drug (SD)
Analgesics 0.58 (0.35) 0.56 (0.37) 0.60
Antibiotics 0.08 (0.19) 0.13 (0.0.28) 0.34
Anti-inflammatories 0.14 (0.0.21) 0.16 (0.0.27) 0.24
Anticoagulant 0.05 (0.16) 0.03 (0.14) 0.84
Anti-inflammatory gels 0.01 (0.06) 0 (0.04) 0.74
Other 0.15 (0.29) 0.11 (0.25) 0.82
All medicines 1.00 1.00 0.98
PSS, number of contacts (SE)
Laundry services 0 0
Social worker contacts 0 0.01 (0.01) 0.16
Care worker/home help 0.43 (0.43) 0.74 (0.56) 0.33
Other 0.60 (0.42) 0 0.92
Total PSS use 1.02 (0.60) 0.75 (0.56) 0.63
Productivity losses (SD)
Number of days off work 46.12 (4.21) 54.46 (3.72) 0.07*
Six-month follow-up
Subsequent inpatient care, mean length of stay in days (SE)
Orthopaedics
Leg 0 0.08 (0.08) 0.04
Other bones 0 0
Rehabilitation unit 0 0
Other
Surgery 0 0.03 (0.03) 0.16
Non-surgery 0 0.01 (0.01)
Total inpatient care use 0 0.11 (0.06) 0.03**
Outpatient care, mean number of contacts (SE)
Orthopaedics 0.71 (0.10) 1.17 (0.25) 0.04
Pathology 0.05 (0.02) 0.02 (0.02) 0.89
Radiology
Radiography 0.53 (0.09) 0.71 (0.10) 0.1
Magnetic resonance imaging 0.01 (0.01) 0.01 (0.01) 0.5
Computerised tomography 0.02 (0.01) 0.02 (0.01) 0.5
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TABLE 37 Use of health-care resources related to distal fracture fixation by each follow-up period and treatment
arm (complete cases) (continued )
Health-care resource
Treatment group
Difference:
p-value of t-testIM nail fixation Locking plate
Physiotherapy
NHS 1.84 (0.28) 2.53 (0.36) 0.07*
Private 0.27 (0.12) 0.12 (0.06) 0.88
Emergency department
Fracture related 0.02 (0.01) 0.01 (0.01) 0.72
Other reasons 0.02 (0.01) 0.07 (0.05) 0.18
Other 0.16 (0.09) 0.13 (0.06) 0.59
Total outpatient care use 3.64 (0.35) 4.78 (0.53) 0.04**
Community health care
GP contacts
Surgery consultation 1.09 (0.18) 0.89 (0.25) 0.74
Home visit 0.06 (0.04) 0.11 (0.08) 0.30
Telephone calls 0.18 (0.09) 0.14 (0.08) 0.62
Practice nurse contacts 0.06 (0.04) 0.07 (0.05) 0.43
District nurse contacts 0.18 (0.13) 0.43 (0.43) 0.29
Community physiotherapy contacts 1.70 (0.59) 1.04 (0.38) 0.82
Occupational therapy contacts 0.15 (0.09) 0.46 (0.43) 0.24
Other 0.15 (0.10) 0.54 (0.37) 0.16
Total community health-care use 3.58 (0.61) 3.68 (0.67) 0.46
Aids and adaptations
Crutches 0.16 (0.04) 0.19 (0.05) 0.32
Stick 0.09 (0.03) 0.05 (0.02) 0.91
Walking frame 0.02 (0.01) 0.04 (0.02) 0.26
Grab rail 0.06 (0.04) 0.01 (0.01) 0.90
Dressing aids 0.03 (0.03) 0 0.84
Long-handle shoe horn 0.01 (0.01) 0 0.84
Other 0.09 (0.04) 0.13 (0.04) 0.24
Total use – aids and adaptations 0.47 (0.12) 0.41 (0.09) 0.65
Medicines, proportion prescribed each class of drug (SD)
Analgesics 0.51 (0.45) 0.56 (0.46) 0.32
Antibiotics 0.08 (0.24) 0.13 (0.34) 0.50
Anti-inflammatories 0.07 (0.23) 0.02 (0.10) 0.79
Anticoagulant 0.01 (0.08) 0.01 (0.05) 0.50
Anti-inflammatory gels 0.06 (0.23) 0.04 (0.18) 0.68
Other 0.27 (0.42) 0.25 (0.39) 0.58
All medicines 1.00 1.00
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TABLE 37 Use of health-care resources related to distal fracture fixation by each follow-up period and treatment
arm (complete cases) (continued )
Health-care resource
Treatment group
Difference:
p-value of t-testIM nail fixation Locking plate
PSS, number of contacts (SE)
Laundry services 0 0
Social worker contacts 0 0
Care worker/home help 2.43 (1.75) 0.71 (0.71) 0.82
Other 0 0
Total PSS use 2.43 (1.75) 0.71 (0.71) 0.82
Productivity losses (SD)
Number of days off work 24.59 (5.22) 32.80 (5.89) 0.15
Twelve-month follow-up
Subsequent inpatient care, mean length of stay in days (SE)
Orthopaedics
Leg 0.16 (0.10) 0.15 (0.09) 0.95
Other bones 0 0
Rehabilitation unit 0 0
Other
Surgery 0.01 (0.01) 0.10 (0.08) 0.28
Non-surgery 0 0
Total inpatient care 0.17 (0.11) 0.25 (0.15) 0.71
Outpatient care, mean number of contacts (SE)
Orthopaedics 0.46 (0.13) 0.71 (0.18) 0.28
Pathology 0.13 (0.07) 0.27 (0.17) 0.46
Radiology
Radiography 0.38 (0.09) 0.30 (0.08) 0.50
Magnetic resonance imaging 0 0.03 (0.01) 0.08
Computerised tomography 0. 75 (0.46) 0.11 (0.06) 0.17
Physiotherapy
NHS 0.55 (0.22) 0.70 (0.28) 0.67
Private 0.07 (0.05) 0.07 (0.05) 0.97
Emergency department
Fracture related 0.03 (0.02) 0.17 (0.16) 0.36
Other reasons 0.01 (0.01) 0. 03 (0.03) 0.38
Other 0.10 (0.03) 0.31 (0.21) 0.33
Total outpatient care use 2.47 (0.71) 2.70 (0.58) 0.80
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TABLE 37 Use of health-care resources related to distal fracture fixation by each follow-up period and treatment
arm (complete cases) (continued )
Health-care resource
Treatment group
Difference:
p-value of t-testIM nail fixation Locking plate
Community health care, mean number of contacts (SE)
GP contacts
Surgery consultation 0.91 (0.26) 1.64 (0.37) 0.11
Home visit 0.06 (0.04) 0 0.16
Telephone call 0.91 (0.75) 0.03 (0.03) 0.25
Practice nurse contacts 0.09 (0.07) 0.42 (0.20) 0.14
District nurse contacts 0 0
Community physiotherapy contacts 0.69 (0.33) 1.11 (0.59) 0.54
Occupational therapy contacts 0 0.89 (0.68) 0.20
Other 0.09 (0.09) 0.28 (0.22) 0.45
Total community health-care use 2.75 (0.95) 4.36 (1.02) 0.25
Aids and adaptations, mean number of items (SE)
Crutches 0.13 (0.05) 0.06 (0.03) 0.30
Stick 0.03 (0.02) 0.07 (0.02) 0.13
Walking frame 0 0.02 (0.01) 0.58
Grab rail 0.01 (0.01) 0.02 (0.01) 0.10
Dressing aids 0.02 (0.02) 0 0.32
Long-handle shoe horn 0 0.02 (0.01) 0.16
Other 0.14 (0.05) 0.10 (0.04) 0.53
Total use – aids and adaptations 0.35 (0.09) 0.27 (0.07) 0.45
Medicines, proportion prescribed each class of drug (SD)
Analgesics 0.55 (0.43) 0.47 (0.42) 0.73
Antibiotics 0.08 (0.24) 0.05 (0.14) 0.66
Anti-inflammatories 0.20 (0.34) 0.19 (0.35) 0.42
Anticoagulant 0.03 (0.11) 0 0.84
Anti-inflammatory gels 0.08 (0.24) 0 0.91
Other 0.08 (0.24) 0.29 (0.43) 0.03**
All medicines 1.00 1.00
PSS, mean number of contacts (SE)
Laundry services 0 0.02 (0.02) 0.16
Social worker contacts 0.01 (0.01) 0.04 (0.04) 0.24
Care worker/home help 0 0.01 (0.01) 0.16
Other 0 0.01 (0.01) 0.16
Total PSS use 0.01 (0.01) 0.08 (0.05) 0.09*
Productivity losses (SD)
Mean number of days off work 12.99 (5.84) 15.59 (4.91) 0.73
*, significant at the 5% level; **, significant at the 10% level.
GP, general practitioner.
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Appendix 5 Follow-up data
TABLE 38 Follow-up patterns in the UK FixDT trial
Time point
Number of participants (%)Baseline 3 months 6 months 12 months
C C C C 240 (75)
C C C M 18 (6)
C C M M 11 (3)
C M C C 11 (3)
C M M M 10 (3)
C M C M 10 (3)
C M W W 3 (1)
C M M C 4 (1)
C C C D 2 (1)
M W W W 2 (1)
C C M C 2 (1)
C C D D 1 (< 1)
C D D D 1 (< 1)
C M M W 1 (< 1)
M M C C 1 (< 1)
C C C W 1 (< 1)
C W W W 1 (< 1)
C M C W 1 (< 1)
C C M D 1 (< 1)
C, completed DRI questionnaire; D, death; M, missing questionnaire; W, withdrawal from follow-up.
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Appendix 6 Protocol amendments
TABLE 39 List of amendments to the trial protocol
Version
Date of approval Reason for changeAmendment number Date
1 19 December 2012 2 January 2013 Alteration of filter question 7
2 17 March 2013 5 April 2013 Changes in participant ‘consent’
3 N/A N/A N/A
4 14 August 2013 14 October 2013 Data collection in clinic
5 30 October 2013 22 November 2013 Change in eligibility criteria
6 1 March 2014 12 March 2014 Clarification of eligibility criteria
7 N/A N/A N/A
8 21 May 2014 20 June 2014 Updated the contact details of the sponsor and
trial staff details and added main phase sites
9 24 June 2014 22 July 2014 Clarification on how the randomisation is
implemented
10 26 February 2015 20 April 2015 Opt-in option for long-term follow-up at the
outset of the study and addendum foot
pressure walking study
N/A, not applicable.
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Appendix 7 Patient information sheet
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Appendix 8 Consent form
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Appendix 9 Background information
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Appendix 10 Baseline questionnaire
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The EQ-5D-3L has been reproduced with permission.
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UK (English) © 1990 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group
Health Questionnaire
English version for the UK
(Validated for Ireland)
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By placing a tick in one box in each group below, please indicate which statements best 
describe your own health state today.
Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed
Self-Care
I have no problems with self-care
I have some problems washing or dressing myself
I am unable to wash or dress myself
Usual Activities (e.g. work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
Pain / Discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
Anxiety / Depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed
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UK (English) © 1990 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group
9 0
8 0
7 0
6 0
5 0
4 0
3 0
2 0
1 0
100
0
To help people say how good or bad a health state is, 
we have drawn a scale (rather like a thermometer) on 
which the best state you can imagine is marked 100 and 
the worst state you can imagine is marked 0.
We would like you to indicate on this scale how good or 
bad your own health is today, in your opinion. Please do 
this by drawing a line from the box below to whichever 
point on the scale indicates how good or bad your health 
state is today.
Best imaginable 
health state
Worst imaginable 
health state
Your own health 
state today
APPENDIX 10
UK (English) © 1990 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group
130
DOI: 10.3310/hta22250 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 25
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Costa et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
131

Appendix 11 Randomisation process
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Appendix 12 Operation note
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Appendix 13 Six-week follow-up form
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Appendix 14 Serious adverse event form
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Appendix 15 Diagnostic plots for primary
outcome model
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FIGURE 12 Quantile–quantile plot evaluating residuals against the inverse normal distribution, using residuals from
the primary outcome analyses (DRI score at 12 months).
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